<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0169">
    <title>146 Cryptosporidium</title>
    <sect1 id="ch0169s0001">
      <title>146 Cryptosporidium</title>
      <anchor id="ch0169s000001a0001"/>
      <anchor id="ch0169s000000a0001"/>
      <para id="ch0169s000000p0001" role="chapterAuthor">LIHUA XIAO AND YAOYU FENG</para>
      <para id="ch0169s000000p0002"><emphasis>Cryptosporidium</emphasis> spp. are protozoan parasites that inhabit the brush borders of the gastrointestinal and respiratory epithelium of various vertebrates, causing enterocolitis, diarrhea, and cholangiopathy in humans (<link linkend="ch0169s000000li0001">1</link>). In immunocompetent children and adults, cryptosporidiosis is usually a short-term illness accompanied by watery diarrhea, nausea, vomiting, and weight loss. In immunocompromised persons, however, the infection can be protracted and life-threatening. In low- and middle-income countries, cryptosporidiosis is one of the most important causes of moderate to severe diarrhea and diarrhea-associated death (<link linkend="ch0169s000000li0002">2</link>–<link linkend="ch0169s000000li0004">4</link>). For example, in 2016, cryptosporidiosis was the fifth leading cause of diarrhea in children younger than 5 years globally, and caused &gt;48,000 deaths (<link linkend="ch0169s000000li0005">5</link>). <emphasis>Cryptosporidium</emphasis> spp. are well-recognized water- and foodborne pathogens in industrialized nations, having caused many outbreaks of human illness (<link linkend="ch0169s000000li0006">6</link>).</para>
      <para id="ch0169s000000p0003">In addition to causing clinical disease, cryptosporidiosis poses heavy economic burdens. It was estimated that the annual economic costs of cryptosporidiosis in children under 1 year were US$41.5 million, $37.4 million, and $9.6 million in Peru, Kenya, and Bangladesh, respectively (<link linkend="ch0169s000000li0007">7</link>). The estimated annual cost of hospitalization alone due to cryptosporidiosis in the United States is $45 million, with per-case cost of $16,797 (<link linkend="ch0169s000000li0008">8</link>). One large drinking water-associated outbreak of cryptosporidiosis in Ireland was estimated to have caused $22.4 million in economic costs (<link linkend="ch0169s000000li0009">9</link>).</para>
      <sect2 id="ch0169s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0169s000001a0002"/>
        <anchor id="ch0169s000000a0002"/>
        <para id="ch0169s000000p0004"><emphasis>Cryptosporidium</emphasis> spp. are members of the Conoidasida group of the Apicomplexa (Alveolata: Apicomplexa). While <emphasis>Cryptosporidium</emphasis> spp. are traditionally grouped with the coccidia, which include <emphasis>Cyclospora</emphasis> and <emphasis>Cystoisospora</emphasis>, they are phylogenetically more related to the Gregarinasina group (<link linkend="ch0169s000000li0010">10</link>).</para>
        <para id="ch0169s000000p0005">The taxonomy of<emphasis>Cryptosporidium</emphasis> has gone through revisions as the result of extensive molecular genetic studies and biologic characterizations of parasites from various animals (<link linkend="ch0169s000000li0011">11</link>). There are over 40 established <emphasis>Cryptosporidium</emphasis> species (<anchor id="ch0169s000000a0003"/><link linkend="ch0169s000000a0007">Table 1</link>). Some of the common species in vertebrates include <emphasis>C. hominis</emphasis> in humans and nonhuman primates; <emphasis>C. parvum</emphasis> in humans and preweaned ruminants; <emphasis>C. andersoni, C. bovis</emphasis>, and <emphasis>C. ryanae</emphasis> in weaned calves and adult cattle; <emphasis>C. ubiquitum</emphasis> and <emphasis>C. xiaoi</emphasis> in sheep and goats; <emphasis>C. suis</emphasis> and <emphasis>C. scrofarum</emphasis> in pigs; <emphasis>C. canis</emphasis> in dogs; <emphasis>C. felis</emphasis> in cats; <emphasis>C. cuniculus</emphasis> in rabbits; <emphasis>C. wrairi</emphasis> and <emphasis>C. homai</emphasis> in guinea pigs; <emphasis>C. tyzzeri, C. viatorum, C. muris</emphasis>, and <emphasis>C. proliferans</emphasis> in rodents; <emphasis>C. fayeri</emphasis> and <emphasis>C. macropodum</emphasis> in marsupials; <emphasis>C. meleagridis, C. baileyi, C. galli</emphasis>, and <emphasis>C. avium</emphasis> in birds; <emphasis>C. varanii</emphasis> and <emphasis>C. serpentis</emphasis> in reptiles; <emphasis>C. fragile</emphasis> in amphibians; and <emphasis>C. molnari</emphasis> and <emphasis>C. huwi</emphasis> in fish (<link linkend="ch0169s000000a0007">Table 1</link>). There are also over 100 host-adapted <emphasis>Cryptosporidium</emphasis> genotypes that do not yet have species names, such as <emphasis>Cryptosporidium</emphasis> horse, skunk, and chipmunk genotypes I and II and deer mouse genotypes I to III (<link linkend="ch0169s000000li0011">11</link>). These species/genotypes biologically, morphologically, and phylogenetically belong to three groups: intestinal, gastric, and piscine species/genotypes (<link linkend="ch0169s000000li0012">12</link>). Some of these <emphasis>Cryptosporidium</emphasis> species and genotypes, almost all of them from mammals, have been found in humans (<link linkend="ch0169s000000a0007">Table 1</link>).</para>
      </sect2>
      <sect2 id="ch0169s0001s0002">
        <title>DESCRIPTION OF AGENT</title>
        <anchor id="ch0169s000001a0003"/>
        <anchor id="ch0169s000000a0004"/>
        <para id="ch0169s000000p0006"><emphasis>Cryptosporidium</emphasis> spp. are intracellular protozoan parasites that primarily infect epithelial cells of the intestine and biliary ducts, especially the ileum and colon (<anchor id="ch0169s000000a0005"/><link linkend="ch0169s000000a0012">Fig. 1</link>). In severely immunosuppressed persons, the entire gastrointestinal tract and sometimes the respiratory tract are involved. The involvement of the respiratory system in immunocompetent persons may be more common than previously believed, although its role in cryptosporidiosis transmission is not yet clear (<link linkend="ch0169s000000li0013">13</link>). The infection site varies according to species, but almost the entire development of <emphasis>Cryptosporidium</emphasis> spp. occurs between the two lipoprotein layers of the membrane of the epithelial cells.</para>
        <para id="ch0169s000000p0007"><emphasis>Cryptosporidium</emphasis> infections in humans or other susceptible hosts start with the ingestion of oocysts, which, unlike those from <emphasis>Cyclospora</emphasis> spp. and <emphasis>Cystoisospora</emphasis> spp., are fully sporulated upon excretion (<anchor id="ch0169s000000a0006"/><link linkend="ch0169s000000a0013">Fig. 2</link>). Upon contact with gastric and duodenal fluid, four sporozoites are liberated from each excysted oocyst; these invade the epithelial cells, develop into trophozoites surrounded by a parasitophorous vacuole, and undergo two or three generations of asexual multiplication and one generation of sexual reproduction, leading to the formation of new oocysts. All these developmental stages occur between the two layers of the membrane of the epithelial cells. The oocysts sporulate <emphasis>in situ</emphasis>, are excreted into the environment with feces, and can initiate infection in a new host upon ingestion without further development (<link linkend="ch0169s000000a0013">Fig. 2</link>). The time from ingestion of infective oocysts to the completion of endogenous development and excretion of new oocysts varies with species, hosts, and infection doses; it is usually 4 to 10 days. In addition to the classic coccidian developmental stages, a gregarine-like extracellular stage was described, which supposedly can go through multiplication via syzygy, a sexual reproduction process involving the end-to-end fusion of two or more parasites (<link linkend="ch0169s000000li0014">14</link>).</para>
        <table id="ch0169s000000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0169s000000a0007"/><link linkend="ch0169s000000a0003">TABLE 1</link></phrase></emphasis> <emphasis>Cryptosporidium</emphasis> species, hosts, and human infectivity<superscript><emphasis><anchor id="ch0169s000000a0008"/><link linkend="ch0169s000000a0010">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="5">
            <tbody>
              <row>
                <entry>Species</entry>
                <entry><phrase role="center">Oocyst size (µm)</phrase>
                </entry>
                <entry><phrase role="center">Length/width ratio</phrase>
                </entry>
                <entry><phrase role="center">Major hosts</phrase>
                </entry>
                <entry><phrase role="center">Reports in humans<superscript><emphasis><link linkend="ch0169s000000a0010">b</link></emphasis></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis role="strong">Intestinal</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis role="strong">C. alticolis</emphasis>
                </entry>
                <entry>4.9–5.7 × 4.6–5.2</entry>
                <entry>1.00–1.20</entry>
                <entry>Voles</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. apodemi</emphasis>
                </entry>
                <entry>3.9–4.7 × 3.8–4.4</entry>
                <entry>1.00–1.06</entry>
                <entry>Mice</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. avium</emphasis>
                </entry>
                <entry>5.3–6.9 × 4.3–5.5</entry>
                <entry>1.14–1.47</entry>
                <entry>Birds</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. baileyi</emphasis>
                </entry>
                <entry>6.0–7.5 × 4.8–5.7</entry>
                <entry>1.05–1.79</entry>
                <entry>Birds</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. bovis</emphasis>
                </entry>
                <entry>4.76–5.35 × 4.17–4.76</entry>
                <entry>1.06</entry>
                <entry>Bovids</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. canis</emphasis>
                </entry>
                <entry>3.68–5.88 × 3.68–5.88</entry>
                <entry>1.04–1.06</entry>
                <entry>Canids</entry>
                <entry>Many</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. cuniculus</emphasis>
                </entry>
                <entry>4.74–5.75 × 4.32–5.21</entry>
                <entry>1.11</entry>
                <entry>Rabbits</entry>
                <entry>Many</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. ditrichi</emphasis>
                </entry>
                <entry>4.5–5.2 × 4.0–4.6</entry>
                <entry>1.0–1.2</entry>
                <entry>Mice</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. ducismarci</emphasis>
                  <superscript>
                    <emphasis>
                      <anchor id="ch0169s000000a0009"/>
                      <link linkend="ch0169s000000a0011">c</link>
                    </emphasis>
                  </superscript>
                </entry>
                <entry>4.4–5.4 × 4.3–5.3</entry>
                <entry>1.1 ± 0.03</entry>
                <entry>Tortoises</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. erinacei</emphasis>
                </entry>
                <entry>4.5–5.8 × 4.0–4.8</entry>
                <entry>1.02–1.35</entry>
                <entry>Hedgehogs, horses</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. fayeri</emphasis>
                </entry>
                <entry>4.5–5.1 × 3.8–5.0</entry>
                <entry>1.02–1.18</entry>
                <entry>Marsupials</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. felis</emphasis>
                </entry>
                <entry>5.0 × 4.5</entry>
                <entry>Unknown</entry>
                <entry>Felids</entry>
                <entry>Many</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. fragile</emphasis>
                </entry>
                <entry>5.5–7.0 × 5.0–6.5</entry>
                <entry>1.0–1.3</entry>
                <entry>Amphibians</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. homai</emphasis>
                </entry>
                <entry>Unknown</entry>
                <entry>Unknown</entry>
                <entry>Guinea pigs</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. hominis</emphasis>
                </entry>
                <entry>4.4–5.4 × 4.4–5.9</entry>
                <entry>1.01–1.09</entry>
                <entry>Humans</entry>
                <entry>Most common</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. macropodum</emphasis>
                </entry>
                <entry>4.5–6.0 × 5.0–6.0</entry>
                <entry>1.1</entry>
                <entry>Marsupials</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. meleagridis</emphasis>
                </entry>
                <entry>4.5–6.0 × 4.2–5.3</entry>
                <entry>1.00–1.33</entry>
                <entry>Birds and humans</entry>
                <entry>Many</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. microti</emphasis>
                </entry>
                <entry>3.9–4.7 × 3.8–4.4</entry>
                <entry>1.00–1.06</entry>
                <entry>Voles</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. myocastoris</emphasis>
                </entry>
                <entry>4.8–5.2 × 4.7–5.0</entry>
                <entry>1.00–1.08</entry>
                <entry>Rodents</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. occultus</emphasis>
                </entry>
                <entry>4.66–5.53 × 4.47–5.44</entry>
                <entry>1.00–1.17</entry>
                <entry>Rats</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. ornithophilus</emphasis>
                </entry>
                <entry>5.24–6.77 × 4.68–5.50</entry>
                <entry>1.06–1.36</entry>
                <entry>Birds</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. parvum</emphasis>
                </entry>
                <entry>4.5–5.4 × 4.5–5.4</entry>
                <entry>1.0–1.3</entry>
                <entry>Ruminants and humans</entry>
                <entry>Second most common</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. ratti</emphasis>
                </entry>
                <entry>4.4–5.4 × 4.3–5.1</entry>
                <entry>1.0–1.1</entry>
                <entry>Rats</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. rubeyi</emphasis>
                  <emphasis>c</emphasis>
                </entry>
                <entry>4.4–5.0 × 4.0–5.0</entry>
                <entry>1.08</entry>
                <entry>Squirrels</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. ryanae</emphasis>
                </entry>
                <entry>2.94–4.41 × 2.94–3.68</entry>
                <entry>1.18</entry>
                <entry>Bovids</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. scrofarum</emphasis>
                </entry>
                <entry>4.81–5.96 × 4.23–5.29</entry>
                <entry>1.07 ± 0.06</entry>
                <entry>Pigs</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. suis</emphasis>
                </entry>
                <entry>4.4–4.9 × 4.0–4.3</entry>
                <entry>1.1</entry>
                <entry>Pigs</entry>
                <entry>Some</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. tyzzeri</emphasis>
                </entry>
                <entry>4.64 ± 0.05 × 4.19 ± 0.06</entry>
                <entry>1.11 ± 0.06</entry>
                <entry>Rodents</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. ubiquitum</emphasis>
                </entry>
                <entry>4.71–5.32 × 4.33–4.98</entry>
                <entry>1.08</entry>
                <entry>Ruminants, rodents, primates</entry>
                <entry>Many</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. varanii (syn. C. saurophilum)</emphasis>
                </entry>
                <entry>4.8–5.1 × 4.4–4.8</entry>
                <entry>1.03 ± 0.03</entry>
                <entry>Lizards</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. viatorum</emphasis>
                </entry>
                <entry>1.03 ± 0.03</entry>
                <entry>1.03–1.32</entry>
                <entry>Rats</entry>
                <entry>Many</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. wrairi</emphasis>
                </entry>
                <entry>4.0–5.0 × 4.8–5.6</entry>
                <entry>Unknown</entry>
                <entry>Guinea pigs</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. xiaoi</emphasis>
                </entry>
                <entry>2.94–4.41 × 2.94–4.41</entry>
                <entry>1.15</entry>
                <entry>Sheep and goats</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">Gastric</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis role="strong">C. andersoni</emphasis>
                </entry>
                <entry>6.0–8.1 × 5.0–6.5</entry>
                <entry>1.07–1.50</entry>
                <entry>Bovids, goats, and hamsters</entry>
                <entry>Few</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. galli</emphasis>
                </entry>
                <entry>8.0–8.5 × 6.2–6.4</entry>
                <entry>1.3</entry>
                <entry>Birds</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. muris</emphasis>
                </entry>
                <entry>6.6–7.9 × 5.3–6.5</entry>
                <entry>1.1–1.5</entry>
                <entry>Rodents</entry>
                <entry>Some</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. proliferans</emphasis>
                </entry>
                <entry>6.8–8.8 × 4.8–6.2</entry>
                <entry>1.48</entry>
                <entry>Rodents</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. proventriculi</emphasis>
                </entry>
                <entry>6.70–8.40 × 5.10–6.3</entry>
                <entry>1.08–1.41</entry>
                <entry>Birds</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. serpentis</emphasis>
                </entry>
                <entry>6.3 × 5.5</entry>
                <entry>1.14 ± 0.11</entry>
                <entry>Snakes and lizards</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. testudinis</emphasis>
                  <superscript>
                    <emphasis>
                      <link linkend="ch0169s000000a0011">c</link>
                    </emphasis>
                  </superscript>
                </entry>
                <entry>5.8–6.9 × 5.3–6.5</entry>
                <entry>1.1 ± 0.05</entry>
                <entry>Tortoises</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">Piscine</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis role="strong">C. abrahamseni</emphasis>
                </entry>
                <entry>3.82 ± 0.22 × 3.16 ± 0.18</entry>
                <entry>1.22</entry>
                <entry>Fish</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. bollandi</emphasis>
                </entry>
                <entry>3.11 × 2.82</entry>
                <entry>Unknown</entry>
                <entry>Fish</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. huwi</emphasis>
                </entry>
                <entry>4.4–4.9 × 4.0–4.8</entry>
                <entry>0.92–1.35</entry>
                <entry>Fish</entry>
                <entry>No</entry>
              </row>
              <row>
                <entry><emphasis role="strong">C. molnari</emphasis>
                </entry>
                <entry>3.23–5.45 × 3.02–5.04</entry>
                <entry>1.00–1.17</entry>
                <entry>Fish</entry>
                <entry>No</entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0169s000000a0010"/><link linkend="ch0169s000000a0008">a</link></emphasis></superscript>Based on references <link linkend="ch0169s000000li0011">11</link> and<link linkend="ch0169s000000li0265"> 265</link>.</para>
        <para role="table-footnote"><superscript><emphasis>b</emphasis></superscript>Few, under 5 confirmed cases or reports (excluding uncertain reports); some, 5 to 10 confirmed cases or reports; many, over 10 confirmed cases or reports.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0169s000000a0011"/><link linkend="ch0169s000000a0009">c</link></emphasis></superscript>Infection site is based on phylogeny inference.</para>
        <para id="ch0169s000000p0008">Currently, approximately 20<emphasis>Cryptosporidium</emphasis> species have been reported in humans, including <emphasis>C. hominis, C. parvum, C. meleagridis, C. felis, C. canis, C. cuniculus, C. ubiquitum, C. viatorum, C. muris, C. andersoni, C. bovis, C. ditrichi, C. erinacei, C. fayeri, C. occultus, C. scrofarum, C. suis, C. tyzzeri, C. wrairi</emphasis>, and <emphasis>C. xiaoi</emphasis> (<link linkend="ch0169s000000a0007">Table 1</link>). Several <emphasis>Cryptosporidium</emphasis> genotypes of known species status, such as the horse, skunk, mink, and chipmunk I genotypes, have also been found in humans (<link linkend="ch0169s000000li0015">15</link>, <link linkend="ch0169s000000li0016">16</link>). Humans are most frequently infected with <emphasis>C. hominis</emphasis> and <emphasis>C. parvum.</emphasis> The former almost exclusively infects humans and nonhuman primates and thus is considered an anthroponotic parasite, whereas the latter mostly infects humans and ruminants and thus is considered a zoonotic pathogen. Other species, such as <emphasis>C. meleagridis, C. felis, C. canis, C. cuniculus, C. ubiquitum, C. viatorum, C. muris</emphasis>, and chipmunk genotype I are less common. The remaining <emphasis>Cryptosporidium</emphasis> species and genotypes have been found in only a few human cases (<link linkend="ch0169s000000a0007">Table 1</link>). These <emphasis>Cryptosporidium</emphasis> spp. infect both immunocompetent and immunocompromised persons. The distribution of these species in humans is different among geographic areas and socioeconomic conditions, with <emphasis>C. meleagridis, C. canis</emphasis> and <emphasis>C. felis</emphasis>, and <emphasis>C. viatorum</emphasis> being seen mostly in humans in low- and middle-income countries, <emphasis>C. ubiquitum</emphasis> and chipmunk genotype I being seen mostly in industrialized nations, and <emphasis>C. cuniculus</emphasis> being seen mostly in the United Kingdom and New Zealand (<link linkend="ch0169s000000li0017">17</link>–<link linkend="ch0169s000000li0020">20</link>). This is probably the result of differences in infection sources and transmission routes.</para>
        <figure id="ch0169s000000f0001"><title><phrase role="figureLabel"><anchor id="ch0169s000000a0012"/><link linkend="ch0169s000000a0005"><emphasis role="strong">FIGURE 1</emphasis></link></phrase> <emphasis>Cryptosporidium parvum</emphasis> in the surface of the ileum of mice under transmission electron <emphasis role="strong">(A)</emphasis> and scanning electron <emphasis role="strong">(B)</emphasis> microscopy. In panel A, the organisms are intracellular, but are located between the two lipoprotein layers of the membrane (i.e., intracellular, but extracytoplasmic). Diverse development stages of the pathogen are seen on the surface of the epithelial cells. In panel B, some released merozoites (indicated by arrows) in addition to other stages (the globular structures) are seen.
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0169f05.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <figure id="ch0169s000000f0002"><title><phrase role="figureLabel"><anchor id="ch0169s000000a0013"/><link linkend="ch0169s000000a0006"><emphasis role="strong">FIGURE 2</emphasis></link></phrase> Life cycle of <emphasis>Cryptosporidium</emphasis> spp. Sporulated oocysts, containing four sporozoites, are excreted by the infected host through feces and possibly other routes, such as respiratory secretions <emphasis role="strong">(<link linkend="ch0169s000000li0001">1</link>).</emphasis> Transmission of <emphasis>Cryptosporidium</emphasis> spp. in humans occurs mainly through contact with infected persons (for <emphasis>C. hominis</emphasis> and <emphasis>C. parvum</emphasis>) or animals (mostly for <emphasis>C. parvum</emphasis>) and consumption of contaminated water and food <emphasis role="strong">(<link linkend="ch0169s000000li0002">2</link>).</emphasis> Following ingestion (and possibly inhalation) by a suitable host <emphasis role="strong">(<link linkend="ch0169s000000li0003">3</link>)</emphasis>, excystation <emphasis role="strong">(a)</emphasis> occurs. The sporozoites are released and parasitize epithelial cells <emphasis role="strong">(b, c)</emphasis> of the gastrointestinal tract or other tissues, such as the respiratory tract. In these cells, the parasites undergo asexual multiplication (schizogony/merogony) <emphasis role="strong">(d, e, f)</emphasis> and then sexual multiplication (gametogony), producing microgamonts (male) <emphasis role="strong">(g)</emphasis> and macrogamonts (female) <emphasis role="strong">(h).</emphasis> Upon fertilization of the macrogamonts by the microgametes <emphasis role="strong">(i)</emphasis>, oocysts <emphasis role="strong">(j, k)</emphasis> develop and then sporulate in the infected host. Two different types of oocysts are produced: the thick-walled type, which is commonly excreted from the host <emphasis role="strong">(j)</emphasis>, and the thin-walled oocyst <emphasis role="strong">(k)</emphasis>, which is primarily involved in autoinfection. Oocysts are infective upon excretion, thus permitting direct and immediate fecal-oral transmission (courtesy of DPDx: <ulink url="http://www.cdc.gov/dpdx/">http://www.cdc.gov/dpdx/</ulink>). Note that data from a recent study indicate the presence of three merogony cycles with no clear differentiation of Type I and Type II meronts (<link linkend="ch0169s000000li0266">266</link>).
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0169f06.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0169s0001s0003">
        <title>EPIDEMIOLOGY, TRANSMISSION, AND PREVENTION</title>
        <anchor id="ch0169s000001a0004"/>
        <anchor id="ch0169s000000a0014"/>
        <anchor id="ch0169s000000a0015"/>
        <anchor id="ch0169s000000a0016"/>
        <anchor id="ch0169s000000a0017"/>
        <para id="ch0169s000000p0009"><emphasis>Cryptosporidium</emphasis> spp. have a worldwide distribution, and their oocysts are ubiquitously present in the environment. In the United States, the number of annual reported cases of cryptosporidiosis has increased more than 2-fold since 2005 (<link linkend="ch0169s000000li0021">21</link>). It is estimated that there are about 750,000 cases of cryptosporidiosis in the United States each year, as 98.6% of cases remain undiagnosed or unreported (<link linkend="ch0169s000000li0022">22</link>). In low- and middle-income countries, cryptosporidiosis is one of the most important causes for moderate to severe diarrhea and diarrhea-associated mortality in young children (<link linkend="ch0169s000000li0002">2</link>–<link linkend="ch0169s000000li0004">4</link>). Humans can acquire cryptosporidiosis through several transmission routes, such as direct contact with infected persons or animals and consumption of contaminated water (drinking or recreational) or food (<link linkend="ch0169s000000li0023">23</link>, <link linkend="ch0169s000000li0024">24</link>). However, the relative contribution of each in the transmission of <emphasis>Cryptosporidium</emphasis> infection in humans is unclear. In response to this and the increased national reporting of cryptosporidiosis in recent years, the U.S. Centers for Disease Control and Prevention (CDC) in 2010 launched CryptoNet, the first molecular tracking system for a parasitic infection (<ulink url="https://www.cdc.gov/parasites/crypto/cryptonet.html">https://www.cdc.gov/parasites/crypto/cryptonet.html</ulink>) (<link linkend="ch0169s000000li0025">25</link>). CryptoNet is aimed at the efficient use of existing infrastructure to facilitate the systematic collection and real-time sharing of epidemiologic data and molecular characterization of <emphasis>Cryptosporidium</emphasis> isolates. This allows improved understanding of <emphasis>Cryptosporidium</emphasis> transmission and investigations of cryptosporidiosis outbreaks. The United Kingdom has also maintained a similar molecular surveillance system of cryptosporidiosis at the Cryptosporidium Reference Unit of the Public Health Wales Microbiology and Health Protection.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0169s0002">
      <title>Susceptible Populations</title>
      <anchor id="ch0169s000002a0001"/>
      <anchor id="ch0169s000000a0018"/>
      <para id="ch0169s000000p0010">In low- and middle-income countries, human<emphasis>Cryptosporidium</emphasis> infection occurs mostly in children younger than 2 years and is one of the top five causes of diarrhea in this age group (<link linkend="ch0169s000000li0002">2</link>, <link linkend="ch0169s000000li0003">3</link>, <link linkend="ch0169s000000li0026">26</link>). Immunity against cryptosporidiosis occurrence develops over increased age and repeated exposures, and there is no apparent species-specific protection against clinical cryptosporidiosis (<link linkend="ch0169s000000li0027">27</link>). In industrialized nations, pediatric cryptosporidiosis in children occurs later than it does in low- and middle-income countries, probably due to delayed exposures to contaminated environments as a result of better hygiene (<link linkend="ch0169s000000li0021">21</link>, <link linkend="ch0169s000000li0023">23</link>). Cryptosporidiosis is also common in elderly people attending nursing homes, where person-to-person transmission probably plays a major role in the spread of <emphasis>Cryptosporidium</emphasis> infections (<link linkend="ch0169s000000li0021">21</link>, <link linkend="ch0169s000000li0028">28</link>). In the general population, a substantial number of adults are susceptible to <emphasis>Cryptosporidium</emphasis> infection, as sporadic infections occur in all age groups in the United States and United Kingdom, and traveling to low- and middle-income countries and consumption of contaminated food or water can frequently lead to infection (<link linkend="ch0169s000000li0021">21</link>, <link linkend="ch0169s000000li0023">23</link>, <link linkend="ch0169s000000li0029">29</link>). Cryptosporidiosis is common in immunocompromised persons, including patients with HIV, persons with primary immunodeficiency, and cancer and transplant patients undergoing immunosuppressive therapy (<link linkend="ch0169s000000li0030">30</link>–<link linkend="ch0169s000000li0033">33</link>). Hemodialysis patients with chronic renal failure and renal transplant patients commonly develop cryptosporidiosis (<link linkend="ch0169s000000li0034">34</link>–<link linkend="ch0169s000000li0037">37</link>). In HIV-positive persons, the occurrence of cryptosporidiosis increases as CD4+ lymphocyte cell counts fall, especially below 200 cells/µl (<link linkend="ch0169s000000li0031">31</link>, <link linkend="ch0169s000000li0038">38</link>, <link linkend="ch0169s000000li0039">39</link>).</para>
    </sect1>
    <sect1 id="ch0169s0003">
      <title>Anthroponotic versus Zoonotic Transmission</title>
      <anchor id="ch0169s000003a0001"/>
      <anchor id="ch0169s000000a0019"/>
      <para id="ch0169s000000p0011">Contact with persons with diarrhea has been identified as a major risk factor for sporadic cryptosporidiosis in industrialized countries (<link linkend="ch0169s000000li0029">29</link>, <link linkend="ch0169s000000li0040">40</link>). This is supported by the high prevalence of cryptosporidiosis in day care facilities and nursing homes and among mothers with young children in these countries. Studies in the United States and Europe have further shown that cryptosporidiosis is more common in homosexual men than in persons in other HIV transmission categories (<link linkend="ch0169s000000li0041">41</link>), indicating that direct person-to-person or anthroponotic transmission of cryptosporidiosis is common.</para>
      <para id="ch0169s000000p0012">Only a few case-control studies have assessed the role of zoonotic transmission in the acquisition of cryptosporidiosis in humans. In industrialized countries, contact with farm animals (especially cattle) is a major risk factor for sporadic cases of human cryptosporidiosis (<link linkend="ch0169s000000li0042">42</link>–<link linkend="ch0169s000000li0048">48</link>). Similarly, contact with farm animals has been identified as a risk factor for <emphasis>Cryptosporidium</emphasis> infection in patients with HIV and immunocompetent persons in China, Ethiopia, Nigeria, and Mexico (<link linkend="ch0169s000000li0049">49</link>–<link linkend="ch0169s000000li0053">53</link>). The role of companion animals in the transmission of human <emphasis>Cryptosporidium</emphasis> infection in humans is probably less important (<link linkend="ch0169s000000li0054">54</link>). However, direct transmission of <emphasis>C. canis</emphasis> or <emphasis>C. felis</emphasis> between dogs or cats and humans has been reported (<link linkend="ch0169s000000li0055">55</link>–<link linkend="ch0169s000000li0057">57</link>).</para>
      <para id="ch0169s000000p0013">The distribution of<emphasis>C. parvum</emphasis> and <emphasis>C. hominis</emphasis> in humans is a reflection of the role of different transmission routes in cryptosporidiosis epidemiology. Thus far, studies conducted in low- and middle-income countries have shown a predominance of <emphasis>C. hominis</emphasis> in children or HIV-positive adults (<link linkend="ch0169s000000li0019">19</link>). This is also true for most areas in the United States, Canada, Australia, and Japan. In Europe and New Zealand, however, several studies have shown almost equal prevalence of <emphasis>C. parvum</emphasis> and <emphasis>C. hominis</emphasis> in both immunocompetent and immunocompromised persons (<link linkend="ch0169s000000li0018">18</link>, <link linkend="ch0169s000000li0020">20</link>, <link linkend="ch0169s000000li0038">38</link>, <link linkend="ch0169s000000li0058">58</link>, <link linkend="ch0169s000000li0059">59</link>). In contrast, children in the Middle East are mostly infected with <emphasis>C. parvum</emphasis> (<link linkend="ch0169s000000li0060">60</link>–<link linkend="ch0169s000000li0063">63</link>). The differences in the distribution of <emphasis>Cryptosporidium</emphasis> species in humans are considered an indication of differences in infection sources (<link linkend="ch0169s000000li0017">17</link>); the occurrence of <emphasis>C. hominis</emphasis> in humans is most likely due to anthroponotic transmission, whereas <emphasis>C. parvum</emphasis> in a population can be the result of both anthroponotic and zoonotic transmission. Thus, in most low- and middle-income countries, it is possible that anthroponotic transmission of <emphasis>Cryptosporidium</emphasis> plays a major role in human cryptosporidiosis, whereas in Europe, Australia, New Zealand, and rural areas of the United States, both anthroponotic and zoonotic transmissions could be important.</para>
      <para id="ch0169s000000p0014">Recent subtyping studies based on sequence analyses of the gene encoding the 60-kDa glycoprotein (<emphasis>gp60</emphasis>) have shown that many <emphasis>C. parvum</emphasis> infections in humans are not results of zoonotic transmission (<link linkend="ch0169s000000li0015">15</link>). Among several <emphasis>C. parvum</emphasis> subtype families identified, IIa and IIc are the two most common families. The former has been identified in both humans and ruminants, and thus can be a zoonotic pathogen, whereas the latter has been seen mainly in humans (<link linkend="ch0169s000000li0017">17</link>) and thus is an anthroponotic pathogen. In low- and middle-income countries, most <emphasis>C. parvum</emphasis> infections in children and HIV-positive persons are caused by the subtype family IIc, with IIa being largely absent, indicating that anthroponotic transmission of <emphasis>C. parvum</emphasis> is common in these areas (<link linkend="ch0169s000000li0019">19</link>). In contrast, both IIa and IIc subtype families are seen in humans in industrialized nations, with the former being far more common than the latter. Another <emphasis>C. parvum</emphasis> subtype family commonly found in sheep and goats, IId, is the dominant <emphasis>C. parvum</emphasis> subtype family in humans in Middle East countries (<link linkend="ch0169s000000li0060">60</link>, <link linkend="ch0169s000000li0064">64</link>). Results of multilocus subtyping support the conclusions of <emphasis>gp60</emphasis> subtyping studies (<link linkend="ch0169s000000li0017">17</link>).</para>
      <anchor id="ch0169s000000a0020"/>
      <beginpage pagenum="2880"/>
    </sect1>
    <sect1 id="ch0169s0004">
      <title>Waterborne Transmission</title>
      <anchor id="ch0169s000004a0001"/>
      <anchor id="ch0169s000000a0021"/>
      <para id="ch0169s000000p0015">Epidemiologic studies have frequently identified water as a major route of<emphasis>Cryptosporidium</emphasis> transmission in industrialized nations (<link linkend="ch0169s000000li0006">6</link>, <link linkend="ch0169s000000li0029">29</link>). Seasonal variations in the incidence of human <emphasis>Cryptosporidium</emphasis> infection in the United States and Europe have been partially attributed to waterborne transmission (<link linkend="ch0169s000000li0021">21</link>, <link linkend="ch0169s000000li0065">65</link>). In the United States, there is a late summer peak in sporadic cases of cryptosporidiosis (<link linkend="ch0169s000000li0021">21</link>, <link linkend="ch0169s000000li0066">66</link>), which is largely due to recreational activities such as swimming and water sports (<link linkend="ch0169s000000li0067">67</link>). The role of water in <emphasis>Cryptosporidium</emphasis> infection in low- and middle-income countries is less clear. In most tropical countries, <emphasis>Cryptosporidium</emphasis> infections in children peak during the rainy season, indicating that waterborne transmission could play a potential role in the transmission of cryptosporidiosis in these areas (<link linkend="ch0169s000000li0026">26</link>). In a study conducted in a slum in southern India, however, children drinking bottled water and municipal water had similar incidence of cryptosporidiosis (<link linkend="ch0169s000000li0068">68</link>).</para>
      <para id="ch0169s000000p0016">Numerous waterborne outbreaks of cryptosporidiosis have occurred in the United States, Canada, the United Kingdom, France, Australia, Japan, and other industrialized nations (<link linkend="ch0169s000000li0006">6</link>, <link linkend="ch0169s000000li0067">67</link>, <link linkend="ch0169s000000li0069">69</link>–<link linkend="ch0169s000000li0071">71</link>). These include outbreaks associated with both drinking water and recreational water (swimming pools and water parks). After the massive cryptosporidiosis outbreak in Milwaukee, WI, in 1993, the water industry has adopted more stringent treatments of source water. Currently, the number of drinking water-associated outbreaks is in decline in the United States and United Kingdom, and most outbreaks in the United States are associated with recreational water (<link linkend="ch0169s000000li0021">21</link>, <link linkend="ch0169s000000li0047">47</link>, <link linkend="ch0169s000000li0069">69</link>, <link linkend="ch0169s000000li0070">70</link>, <link linkend="ch0169s000000li0072">72</link>, <link linkend="ch0169s000000li0073">73</link>). <emphasis>C. parvum</emphasis> and <emphasis>C. hominis</emphasis> are responsible for most cryptosporidiosis outbreaks, with <emphasis>C. hominis</emphasis> being responsible for more outbreaks than <emphasis>C. parvum</emphasis> (<link linkend="ch0169s000000li0015">15</link>, <link linkend="ch0169s000000li0074">74</link>). Recently, there was one drinking water-associated cryptosporidiosis outbreak caused by <emphasis>C. cuniculus</emphasis> (<link linkend="ch0169s000000li0075">75</link>). A few small outbreaks of cryptosporidiosis by <emphasis>C. meleagridis</emphasis> and <emphasis>Cryptosporidium</emphasis> chipmunk genotype I have been reported in Japan and Sweden, respectively, although they might not be the result of waterborne transmission (<link linkend="ch0169s000000li0076">76</link>, <link linkend="ch0169s000000li0077">77</link>).</para>
    </sect1>
    <sect1 id="ch0169s0005">
      <title>Foodborne Transmission</title>
      <anchor id="ch0169s000005a0001"/>
      <anchor id="ch0169s000000a0022"/>
      <para id="ch0169s000000p0017">Foodborne transmission is also important in cryptosporidiosis epidemiology (<link linkend="ch0169s000000li0078">78</link>). <emphasis>Cryptosporidium</emphasis> oocysts have been isolated often from fruits, vegetables, and shellfish (<link linkend="ch0169s000000li0079">79</link>–<link linkend="ch0169s000000li0085">85</link>). Direct contamination of food by fecal material from animals or food handlers has been implicated in several foodborne outbreaks of cryptosporidiosis in industrialized nations. In most instances, human infections were usually due to consumption of contaminated fresh produce and unpasteurized apple cider or milk (<link linkend="ch0169s000000li0006">6</link>, <link linkend="ch0169s000000li0086">86</link>–<link linkend="ch0169s000000li0093">93</link>).</para>
      <para id="ch0169s000000p0018">Very few case-control studies have examined the role of contaminated food as a risk factor in the acquisition of<emphasis>Cryptosporidium</emphasis> infection (<link linkend="ch0169s000000li0040">40</link>, <link linkend="ch0169s000000li0094">94</link>). A pediatric study in Brazil failed to show any association between <emphasis>Cryptosporidium</emphasis> infection and diet or type of food hygiene (<link linkend="ch0169s000000li0095">95</link>), although a participatory risk assessment of zoonotic <emphasis>Cryptosporidium</emphasis> infection on dairy farms in urban Dagoretti, Nairobi, Kenya, suggested that consumption of vegetables contaminated by dairy cattle is a potential risk factor (<link linkend="ch0169s000000li0096">96</link>). Case-control studies conducted in the United States, United Kingdom, the Netherlands, and Australia have shown lower prevalence of <emphasis>Cryptosporidium</emphasis> infection in immunocompetent persons with frequent consumption of raw vegetables, probably because of acquired immunity as a result of repeated historical exposures to the pathogen in <emphasis>Cryptosporidium</emphasis>-contaminated fresh produce (<link linkend="ch0169s000000li0040">40</link>, <link linkend="ch0169s000000li0042">42</link>, <link linkend="ch0169s000000li0043">43</link>, <link linkend="ch0169s000000li0097">97</link>, <link linkend="ch0169s000000li0098">98</link>). It is estimated that about 8% of <emphasis>Cryptosporidium</emphasis> infections in the United States are foodborne (<link linkend="ch0169s000000li0022">22</link>).</para>
      <sect2 id="ch0169s0005s0001">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0169s000005a0002"/>
        <anchor id="ch0169s000000a0023"/>
        <para id="ch0169s000000p0019">In low- and middle-income countries, frequent symptoms of cryptosporidiosis in children include diarrhea, abdominal cramps, nausea, vomiting, headache, fatigue, and low-grade fever (<link linkend="ch0169s000000li0026">26</link>). The diarrhea can be voluminous and watery but usually resolves within 1 to 2 weeks without treatment. Not all infected children have diarrhea or other gastrointestinal symptoms, and the occurrence of diarrhea in children with cryptosporidiosis is as low as 30% in community-based studies (<link linkend="ch0169s000000li0027">27</link>, <link linkend="ch0169s000000li0099">99</link>). Even subclinical cryptosporidiosis exerts a significant adverse effect on child growth, as infected children with no clinical symptoms experience growth faltering, both in weight and in height (<link linkend="ch0169s000000li0026">26</link>, <link linkend="ch0169s000000li0100">100</link>–<link linkend="ch0169s000000li0102">102</link>). Children can have multiple episodes of cryptosporidiosis, implying that the anti-<emphasis>Cryptosporidium</emphasis> immunity in children is short-lived or incomplete (<link linkend="ch0169s000000li0027">27</link>, <link linkend="ch0169s000000li0101">101</link>, <link linkend="ch0169s000000li0103">103</link>–<link linkend="ch0169s000000li0105">105</link>). Cryptosporidiosis has been associated with increased mortality in low- and middle-income countries (<link linkend="ch0169s000000li0002">2</link>, <link linkend="ch0169s000000li0106">106</link>), and globally, cryptosporidiosis was the second most important cause of diarrhea-associated mortality in children under 5 years old in 2015 (<link linkend="ch0169s000000li0004">4</link>).</para>
        <para id="ch0169s000000p0020">Unlike in low- and middle-income countries, immunocompetent persons with sporadic cryptosporidiosis in industrialized nations, including children and adults, are more likely to have diarrhea (<link linkend="ch0169s000000li0023">23</link>, <link linkend="ch0169s000000li0100">100</link>). The median number of stools per day during the worst period of the infection is 7 to 9.5 (<link linkend="ch0169s000000li0097">97</link>). Other common symptoms include abdominal pain, nausea, vomiting, and low-grade fever (<link linkend="ch0169s000000li0107">107</link>, <link linkend="ch0169s000000li0108">108</link>). The duration of illness in immunocompetent persons has a mean or median of 9 to 21 days, with a median of 5 loss-of-work or -study days and hospitalization of 7 to 22% of patients (<link linkend="ch0169s000000li0097">97</link>, <link linkend="ch0169s000000li0109">109</link>–<link linkend="ch0169s000000li0111">111</link>). Although these symptoms are generally rare, patients infected with <emphasis>C. hominis</emphasis> are more likely to have joint pain, eye pains, recurrent headache, dizziness, and fatigue than those infected with <emphasis>C. parvum</emphasis> (<link linkend="ch0169s000000li0108">108</link>, <link linkend="ch0169s000000li0112">112</link>). There are significant differences among different <emphasis>Cryptosporidium</emphasis> species and <emphasis>C. hominis</emphasis> subtype families in clinical manifestations of pediatric cryptosporidiosis (<link linkend="ch0169s000000li0103">103</link>). Longer-term sequelae of cryptosporidiosis such as the irritable bowel syndrome have been recognized after the resolution of the infection in industrialized nations (<link linkend="ch0169s000000li0113">113</link>).</para>
        <para id="ch0169s000000p0021">Cryptosporidiosis in immunocompromised persons, including patients with HIV, is frequently associated with chronic, life-threatening diarrhea (<link linkend="ch0169s000000li0114">114</link>). Sclerosing cholangitis and other biliary involvements are also common in patients with advanced HIV infection and other immunocompromised patients with cryptosporidiosis (<link linkend="ch0169s000000li0115">115</link>–<link linkend="ch0169s000000li0119">119</link>). In immunocompromised persons and children in low- and middle-income countries, respiratory system involvement is common in clinical cryptosporidiosis cases, with up to 31% of sputum specimens being positive for <emphasis>Cryptosporidium</emphasis> by PCR (<link linkend="ch0169s000000li0120">120</link>, <link linkend="ch0169s000000li0121">121</link>). Cryptosporidiosis in patients with HIV is associated with increased mortality and shortened survival (<link linkend="ch0169s000000li0122">122</link>). Different <emphasis>Cryptosporidium</emphasis> species and <emphasis>C. hominis</emphasis> subtype families are associated with different clinical manifestations in HIV+ persons in low- and middle-income countries (<link linkend="ch0169s000000li0123">123</link>).</para>
        <anchor id="ch0169s000000a0024"/>
        <beginpage pagenum="2881"/>
      </sect2>
      <sect2 id="ch0169s0005s0002">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0169s000005a0003"/>
        <anchor id="ch0169s000000a0025"/>
        <para id="ch0169s000000p0022">Currently, most active<emphasis>Cryptosporidium</emphasis> infections are diagnosed by analysis of stool specimens. Stool specimens are usually collected fresh or in commercial single vials containing fixative solutions such as 10% buffered formalin, polyvinyl alcohol (PVA), and other chemicals (<link linkend="ch0169s000000li0124">124</link>). However, stool specimens fixed in formalin- and mercury-based preservatives (such as low-viscosity PVA) are suboptimal for molecular diagnosis (<link linkend="ch0169s000000li0125">125</link>). For outbreak investigations, <emphasis>Cryptosporidium</emphasis> spp. present are frequently genotyped and subtyped by PCR methods, which require the use of fresh or frozen stool specimens or stools stored in Cary-Blair transport medium or preserved in PCR-friendly preservatives such as ethanol-based fixatives, zinc PVA, and 2.5% potassium dichromate. It is recommended that, whenever possible, multiple specimens (three specimens passed at intervals of 2 to 3 days) from each patient be examined whenever possible if <emphasis>Cryptosporidium</emphasis> infection is suspected and the examination of initial stool specimen is negative by microscopy, immunoassays, or PCR (<link linkend="ch0169s000000li0124">124</link>). Examinations of intestinal or biliary biopsy specimens and sputum or bronchoalveolar lavage fluid are sometimes used in the diagnosis of cryptosporidiosis in patients with HIV (<link linkend="ch0169s000000li0124">124</link>, <link linkend="ch0169s000000li0126">126</link>).</para>
      </sect2>
      <sect2 id="ch0169s0005s0003">
        <title>DIRECT EXAMINATION</title>
        <anchor id="ch0169s000005a0004"/>
        <anchor id="ch0169s000000a0026"/>
        <para id="ch0169s000000p0023">In clinical laboratories,<emphasis>Cryptosporidium</emphasis> spp. in stool specimens are commonly detected by microscopic examinations of oocysts, immunologic detection of antigens, and nucleic acid amplification testing (<link linkend="ch0169s000000li0127">127</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0169s0006">
      <title>Microscopy</title>
      <anchor id="ch0169s000006a0001"/>
      <anchor id="ch0169s000000a0027"/>
      <para id="ch0169s000000p0024">Stool specimens can be examined directly for<emphasis>Cryptosporidium</emphasis> oocysts by microscopy of direct wet mounts or stained fecal materials if the number of oocysts in specimens is high (<link linkend="ch0169s000000li0128">128</link>). <emphasis>Cryptosporidium</emphasis> oocysts in humans are generally 4 to 6 µm long. Occasionally, <emphasis>C. muris</emphasis> oocysts are also found, which are more elongated (6 to 8 µm) and require the accurate measurement of a substantial number of oocysts in diagnosis (<anchor id="ch0169s000000a0028"/><link linkend="ch0169s000000a0029">Fig 3</link>). Oocysts present can be concentrated by vertical centrifugation, ethyl acetate sedimentation, or sodium chloride or sucrose flotation methods (<link linkend="ch0169s000000li0128">128</link>). Direct wet mounts or wet mounts from concentrated stools can be examined by microscopy in several ways. <emphasis>Cryptosporidium</emphasis> oocysts can be detected by bright-field microscopy. This allows the observation of oocyst morphology and more accurate measurement of oocysts (<link linkend="ch0169s000000a0007">Table 1</link>), which is frequently needed in biologic studies. Differential interference contrast can be used in microscopy, which produces better images and visualization of internal structures of oocysts. Due to the small size of <emphasis>Cryptosporidium</emphasis> oocysts, microscopic examination of wet mounts is not a very sensitive technique.</para>
      <figure id="ch0169s000000f0003"><title><phrase role="figureLabel"><anchor id="ch0169s000000a0029"/><link linkend="ch0169s000000a0028"><emphasis role="strong">FIGURE 3</emphasis></link></phrase> Oocysts of <emphasis>Cryptosporidium hominis</emphasis> (4 to 6 µm) <emphasis role="strong">(A)</emphasis>, <emphasis>Cryptosporidium muris</emphasis> (6 to 8 µm) <emphasis role="strong">(B)</emphasis>, <emphasis>Cyclospora cayetanensis</emphasis> (8 to 10 µm) <emphasis role="strong">(C)</emphasis>, and <emphasis>Cystoisospora belli</emphasis> (20 to 30 by 10 to 20 µm) <emphasis role="strong">(D)</emphasis> stained with modified Ziehl-Neelsen acid-fast stain.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0169f07.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <table id="ch0169s000000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0169s000000a0030"/><link linkend="ch0169s000000a0033">TABLE 2</link></phrase></emphasis> Commercial immunofluorescence assays for microscopy detection of <emphasis>Cryptosporidium</emphasis> oocysts in stool specimens
</title>
        
        <tgroup cols="3">
          <tbody>
            <row>
              <entry><para id="ch0169s000000p0025"><phrase role="center">Product</phrase>
                </para>
              </entry>
              <entry><para id="ch0169s000000p0026"><phrase role="center">Manufacturer or distributor</phrase>
                </para>
              </entry>
              <entry><para id="ch0169s000000p0027"><phrase role="center">Regulatory status</phrase>
                  <superscript>
                    <link linkend="ch0169s000000a0032">a</link>
                  </superscript>
                  <anchor id="ch0169s000000a0031"/>
                </para>
              </entry>
            </row>
            <row>
              <entry>Merifluor<emphasis>Cryptosporidium</emphasis>/<emphasis>Giardia</emphasis></entry>
              <entry>Meridian Biosciences, U.S.,<ulink url="http://www.meridianbioscience.com">http://www.meridianbioscience.com</ulink></entry>
              <entry>FDA/CE</entry>
            </row>
            <row>
              <entry>Crypto Cel</entry>
              <entry>Cellabs, Australia,<ulink url="http://www.cellabs.com.au">http://www.cellabs.com.au</ulink></entry>
              <entry>CE</entry>
            </row>
            <row>
              <entry><emphasis>Cryptosporidium/Giardia</emphasis> DFA</entry>
              <entry>IVD Research Inc., U.S.,<ulink url="http://www.ivdresearch.com">http://www.ivdresearch.com</ulink></entry>
              <entry>FDA</entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><link linkend="ch0169s000000a0031">a</link></superscript><anchor id="ch0169s000000a0032"/>FDA, assay cleared by the U.S. Food and Drug Administration and commercially available in the United States; CE, assay cleared by Conformité Européenne.</para>
      <para id="ch0169s000000p0028">More often,<emphasis>Cryptosporidium</emphasis> oocysts in concentrated stool specimens are detected by microscopy after staining of the fecal smears. Many special stains have been used in the detection of <emphasis>Cryptosporidium</emphasis> oocysts, but modified acid-fast, safranin, and auramine phenol stains are the most commonly used ones (<link linkend="ch0169s000000li0128">128</link>, <link linkend="ch0169s000000li0129">129</link>), especially in low- and middle-income countries, because of their low cost, ease of use, lack of need for special microscopes, and simultaneous detection of several other pathogens such as <emphasis>Cystoisospora</emphasis> and <emphasis>Cyclospora</emphasis> (<link linkend="ch0169s000000a0029">Fig. 3</link>). Two widely used stains are the modified Ziehl-Neelsen acid-fast stain and the modified Kinyoun’s acid-fast stain. Oocysts stain bright red to purple against a blue or green background (<link linkend="ch0169s000000a0029">Fig. 3</link>). Some laboratories have reported sensitive detection of <emphasis>Cryptosporidium</emphasis> oocysts in stool specimens by using fluorescence microscopy with auramine-phenol staining (<link linkend="ch0169s000000li0128">128</link>, <link linkend="ch0169s000000li0130">130</link>).</para>
      <para id="ch0169s000000p0029">Direct fluorescent-antibody assays (DFAs) have been used increasingly in<emphasis>Cryptosporidium</emphasis> oocyst detection by microscopy, especially in industrialized nations. Compared to acid-fast staining, DFA has higher sensitivity and specificity (<link linkend="ch0169s000000li0124">124</link>, <link linkend="ch0169s000000li0128">128</link>). Many commercial DFA kits are marketed for the diagnosis of <emphasis>Cryptosporidium</emphasis>, most of which include reagents allowing simultaneous detection of <emphasis>Giardia</emphasis> cysts (<anchor id="ch0169s000000a0033"/><link linkend="ch0169s000000a0030">Table 2</link>). Oocysts appear apple green against a dark background in immunofluorescence microscopy (<anchor id="ch0169s000000a0034"/><link linkend="ch0169s000000a0035">Fig. 4</link>). It has been shown that DFA can detect oocysts of a broad range of <emphasis>Cryptosporidium</emphasis> species in humans and animals (<link linkend="ch0169s000000li0131">131</link>–<link linkend="ch0169s000000li0134">134</link>).</para>
      <para id="ch0169s000000p0030">Compared to DFA, the sensitivity of most microscopic methods is probably low (<link linkend="ch0169s000000li0134">134</link>). The detection limit for the combination of ethyl acetate concentration and DFA was shown to be 10,000 oocysts per g of liquid stool and 50,000 oocysts per g of formed stool (<link linkend="ch0169s000000li0135">135</link>, <link linkend="ch0169s000000li0136">136</link>). A similar sensitivity was achieved with fecal specimens from dogs (<link linkend="ch0169s000000li0137">137</link>). The sensitivity of modified acid-fast staining was substantially lower than DFA (<link linkend="ch0169s000000li0134">134</link>, <link linkend="ch0169s000000li0136">136</link>), probably because acid-fast stains do not consistently stain all oocysts (<link linkend="ch0169s000000li0138">138</link>). The sensitivity of the DFA can be significantly improved by the incorporation of an oocyst isolation step using an immunomagnetic separation technique (<link linkend="ch0169s000000li0124">124</link>).</para>
      <figure id="ch0169s000000f0004"><title><phrase role="figureLabel"><anchor id="ch0169s000000a0035"/><link linkend="ch0169s000000a0034"><emphasis role="strong">FIGURE 4</emphasis></link></phrase> <emphasis>C. hominis</emphasis> oocysts (4 to 6 µm) and <emphasis>Giardia duodenalis</emphasis> cysts (11 to 14 µm by 7 to 10 µm) under immunofluorescence microscopy.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0169f04.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
    </sect1>
    <sect1 id="ch0169s0007">
      <title>Antigen Detection</title>
      <anchor id="ch0169s000007a0001"/>
      <anchor id="ch0169s000000a0036"/>
      <anchor id="ch0169s000000a0037"/>
      <para id="ch0169s000000p0031"><emphasis>Cryptosporidium</emphasis> infection can also be diagnosed by the detection of <emphasis>Cryptosporidium</emphasis> antigens in stool specimens by immunoassays (<link linkend="ch0169s000000li0129">129</link>). Antigen-capture-based enzymatic immunoassays (EIAs) have been used in the diagnosis of cryptosporidiosis since 1990. EIAs have gained popularity because they do not require experienced microscopists and can be used to screen a large number of samples (<link linkend="ch0169s000000li0127">127</link>). In clinical laboratories, several commercial EIA kits are commonly used (<anchor id="ch0169s000000a0038"/><link linkend="ch0169s000000a0040">Table 3</link>). High specificity (99 to 100%) has been generally reported for these EIA kits (<link linkend="ch0169s000000li0134">134</link>). Sensitivities, however, have been reported to range from 70 to 72% (<link linkend="ch0169s000000li0139">139</link>, <link linkend="ch0169s000000li0140">140</link>) to 94 to 100% (<link linkend="ch0169s000000li0134">134</link>, <link linkend="ch0169s000000li0141">141</link>, <link linkend="ch0169s000000li0142">142</link>). Most EIA kits have been evaluated only with human stool specimens, presumably from patients infected with <emphasis>C. hominis</emphasis> or <emphasis>C. parvum</emphasis> (<link linkend="ch0169s000000li0134">134</link>). Studies should be conducted to evaluate their performance in the detection of human-pathogenic <emphasis>Cryptosporidium</emphasis> species that are significantly divergent from <emphasis>C. hominis</emphasis> and <emphasis>C. parvum</emphasis>, such as <emphasis>C. canis</emphasis> and <emphasis>C. felis</emphasis> (<link linkend="ch0169s000000li0134">134</link>). The usefulness of commercial EIA kits in the detection of <emphasis>Cryptosporidium</emphasis> spp. in animals may also be compromised by the specificity of the antibodies, as shown in the low sensitivity reported in the analysis of samples from animals (<link linkend="ch0169s000000li0143">143</link>).</para>
      <para id="ch0169s000000p0032">Several lateral-flow immunochromatographic assays have been marketed for rapid detection of<emphasis>Cryptosporidium</emphasis> in stool specimens (<anchor id="ch0169s000000a0039"/><link linkend="ch0169s000000a0045">Table 4</link>). These assays have the obvious advantage of point-of-care use without advanced training of technicians. In evaluation studies, these assays have been shown to have high specificities (&gt;85%) and sensitivities (98 to 100%) (<link linkend="ch0169s000000li0140">140</link>, <link linkend="ch0169s000000li0144">144</link>–<link linkend="ch0169s000000li0148">148</link>). In one recent comparative study, the immunochromatographic assay was shown to offer sensitivity and specificity comparable to those of auramine-phenol staining-based fluorescence microscopy (<link linkend="ch0169s000000li0130">130</link>). However, sensitivities of 50 to 75% were shown in some studies for some assays (<link linkend="ch0169s000000li0139">139</link>, <link linkend="ch0169s000000li0143">143</link>, <link linkend="ch0169s000000li0149">149</link>–<link linkend="ch0169s000000li0152">152</link>). This could be attributed partially to the low detection rate of <emphasis>Cryptosporidium</emphasis> species other than <emphasis>C. parvum</emphasis> and <emphasis>C. hominis</emphasis> by these assays (<link linkend="ch0169s000000li0143">143</link>). As a result, it is generally recommended that the detection of <emphasis>Cryptosporidium</emphasis> spp. by EIA and immunochromatographic assay should be confirmed by DFA-based microscopy (<link linkend="ch0169s000000li0128">128</link>). High false-positive rates of several rapid assays in clinical diagnosis of cryptosporidiosis in the United States have been reported (<link linkend="ch0169s000000li0153">153</link>, <link linkend="ch0169s000000li0154">154</link>). This has prompted the Council of State and Territorial Epidemiologists to change the case definition of rapid assay-positive cases from confirmed cases to probable cases. It has also been shown recently that some rapid assay kits have low sensitivity (&lt;35%) in detecting some <emphasis>Cryptosporidium</emphasis> species other than <emphasis>C. hominis</emphasis> and <emphasis>C. parvum</emphasis> (<link linkend="ch0169s000000li0143">143</link>, <link linkend="ch0169s000000li0151">151</link>).</para>
      <table id="ch0169s000000t0003"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0169s000000a0040"/><link linkend="ch0169s000000a0038">TABLE 3</link></phrase></emphasis> Commercial enzymatic immunoassays for the detection of <emphasis>Cryptosporidium</emphasis> antigens in stool specimens<superscript><link linkend="ch0169s000000a0043">a</link></superscript><anchor id="ch0169s000000a0041"/>
</title>
        
        <tgroup cols="3">
          <tbody>
            <row>
              <entry><para id="ch0169s000000p0033"><phrase role="center">Product</phrase>
                </para>
              </entry>
              <entry><para id="ch0169s000000p0034"><phrase role="center">Manufacturer(s) or distributor(s)</phrase>
                </para>
              </entry>
              <entry><para id="ch0169s000000p0035"><phrase role="center">Regulatory status</phrase>
                  <superscript>
                    <link linkend="ch0169s000000a0044">b</link>
                  </superscript>
                  <anchor id="ch0169s000000a0042"/>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>Cryptosporidium</emphasis> II, <emphasis>Giardia</emphasis>/<emphasis>Cryptosporidium</emphasis> Quik Chek, <emphasis>Giardia</emphasis>/<emphasis>Cryptosporidium</emphasis> Chek ELISA</entry>
              <entry>TechLab, U.S.,<ulink url="http://www.techlab.com">http://www.techlab.com</ulink>; Alere, U.S., <ulink url="http://www.alere.com">http://www.alere.com</ulink></entry>
              <entry>FDA/CE</entry>
            </row>
            <row>
              <entry>ProSpecT<emphasis>Cryptosporidium</emphasis>, ProSpecT <emphasis>Giardia</emphasis>/<emphasis>Cryptosporidium</emphasis></entry>
              <entry>ThermoFisher Scientific, U.S.,<ulink url="https://www.thermofisher.com">https://www.thermofisher.com</ulink></entry>
              <entry>FDA/CE</entry>
            </row>
            <row>
              <entry>Ridascreen<emphasis>Cryptosporidium</emphasis></entry>
              <entry>R-Biopharm, Germany,<ulink url="http://www.r-biopharm.com/products/clinical-diagnostics">http://www.r-biopharm.com/products/clinical-diagnostics</ulink></entry>
              <entry>CE</entry>
            </row>
            <row>
              <entry>Tri Combo Parasite Screen (<emphasis>Cryptosporidium, Giardia, Entamoeba histolytica</emphasis>)</entry>
              <entry>TechLab, U.S.,<ulink url="http://www.techlab.com">http://www.techlab.com</ulink>; Alere, U.S., <ulink url="http://www.alere.com">http://www.alere.com</ulink></entry>
              <entry>FDA</entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><link linkend="ch0169s000000a0041">a</link></superscript><anchor id="ch0169s000000a0043"/>Almost all of the assays have been evaluated using only clinical stool specimens from <emphasis>C. hominis</emphasis> and <emphasis>C. parvum.</emphasis> Their sensitivity and specificity for other <emphasis>Cryptosporidium</emphasis> species are unknown.</para>
      <para role="table-footnote"><superscript><link linkend="ch0169s000000a0042">b</link></superscript><anchor id="ch0169s000000a0044"/>FDA, assay cleared by the U.S. Food and Drug Administration and commercially available in the United States; CE, assay cleared by Conformité Européenne.</para>
      <table id="ch0169s000000t0004"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0169s000000a0045"/><link linkend="ch0169s000000a0039">TABLE 4</link></phrase></emphasis> Commercial immunochromatography assays for the detection of <emphasis>Cryptosporidium</emphasis> antigens in stool specimens<superscript><link linkend="ch0169s000000a0048">a</link></superscript><anchor id="ch0169s000000a0046"/>
</title>
        
        <tgroup cols="3">
          <tbody>
            <row>
              <entry><phrase role="center">Product</phrase>
              </entry>
              <entry><phrase role="center">Manufacturer or distributor</phrase>
              </entry>
              <entry><phrase role="center">Regulatory status<superscript><link linkend="ch0169s000000a0049">b</link></superscript></phrase>
                <anchor id="ch0169s000000a0047"/>
              </entry>
            </row>
            <row>
              <entry><emphasis>Giardia/Cryptosporidium</emphasis> Quik Chek</entry>
              <entry>TechLab, Blacksburg, U.S.,<ulink url="http://www.techlab.com">http://www.techlab.com</ulink></entry>
              <entry>FDA/CE</entry>
            </row>
            <row>
              <entry>Immuno<emphasis>Card</emphasis> STAT! <emphasis>Cryptosporidium/Giardia</emphasis> Rapid Assay</entry>
              <entry>Meridian Bioscience, U.S.,<ulink url="http://www.meridianbioscience.com">http://www.meridianbioscience.com</ulink></entry>
              <entry>FDA/CE</entry>
            </row>
            <row>
              <entry>Xpect<emphasis>Cryptosporidium</emphasis> Xpect <emphasis>Giardia/Cryptosporidium</emphasis></entry>
              <entry>ThermoFisher Scientific, U.S.,<ulink url="https://www.thermofisher.com">https://www.thermofisher.com</ulink></entry>
              <entry>FDA/CE</entry>
            </row>
            <row>
              <entry>Crypto-Strip Crypto/<emphasis>Giardia</emphasis> Duo-Strip</entry>
              <entry>Coris BioConcept, Belgium,<ulink url="http://www.corisbio.com">http://www.corisbio.com</ulink></entry>
              <entry>CE</entry>
            </row>
            <row>
              <entry>Crypto Kit</entry>
              <entry>Cypress Diagnostics, Belgium,<ulink url="http://www.diagnostics.be">http://www.diagnostics.be</ulink></entry>
              <entry>CE</entry>
            </row>
            <row>
              <entry><emphasis>Cryptosporidium parvum</emphasis> (Crypto)&#13;
Crypto + <emphasis>Giardia</emphasis>&#13;
Crypto + <emphasis>Giardia</emphasis> + <emphasis>Entamoeba</emphasis></entry>
              <entry>CerTest Biotec, Spain,<ulink url="http://www.certest.es">http://www.certest.es</ulink></entry>
              <entry>CE</entry>
            </row>
            <row>
              <entry>Stick Crypto&#13;
Stick Crypto-<emphasis>Giardia</emphasis>&#13;
Stick Crypto-<emphasis>Giardia</emphasis>-<emphasis>Entamoeba</emphasis></entry>
              <entry>Operon, Spain,<ulink url="http://www.operon.es">http://www.operon.es</ulink></entry>
              <entry>CE</entry>
            </row>
            <row>
              <entry>RIDA Quick<emphasis>Cryptosporidium</emphasis>&#13;
RIDA Quick <emphasis>Cryptosporidium</emphasis>/<emphasis>Giardia</emphasis> Combi&#13;
RIDA Quick <emphasis>Cryptosporidium/Giardia/Entamoeba</emphasis> Combi (dipstick or cassette)</entry>
              <entry>R-Biopharm, Germany,<ulink url="http://www.r-biopharm.com/products/clinical-diagnostics">http://www.r-biopharm.com/products/clinical-diagnostics</ulink></entry>
              <entry>CE</entry>
            </row>
            <row>
              <entry>IVD<emphasis>Cryptosporidium</emphasis> antigen detection assay</entry>
              <entry>IVD Research Inc., U.S.,<ulink url="http://www.ivdresearch.com">http://www.ivdresearch.com</ulink></entry>
              <entry>FDA</entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><link linkend="ch0169s000000a0046">a</link></superscript><anchor id="ch0169s000000a0048"/>Almost all of the assays have been evaluated using only clinical stool specimens from <emphasis>C. hominis</emphasis> and <emphasis>C. parvum.</emphasis> Their sensitivity and specificity for other <emphasis>Cryptosporidium</emphasis> species are unknown.</para>
      <para role="table-footnote"><superscript><link linkend="ch0169s000000a0047">b</link></superscript><anchor id="ch0169s000000a0049"/>FDA, assay cleared by the U.S. Food and Drug Administration and commercially available in the United States; CE, assay cleared by Conformité Européenne.</para>
    </sect1>
    <sect1 id="ch0169s0008">
      <title>Nucleic Acid Amplification Testing</title>
      <anchor id="ch0169s000008a0001"/>
      <anchor id="ch0169s000000a0050"/>
      <anchor id="ch0169s000000a0051"/>
      <para id="ch0169s000000p0036">Molecular techniques, especially PCR and PCR-related methods, have been developed and used in the detection and differentiation of<emphasis>Cryptosporidium</emphasis> spp. for many years (<link linkend="ch0169s000000li0124">124</link>, <link linkend="ch0169s000000li0155">155</link>). They are more sensitive than DFA (<link linkend="ch0169s000000li0130">130</link>, <link linkend="ch0169s000000li0156">156</link>). Some of the PCR assays for <emphasis>Cryptosporidium</emphasis> spp. are commercially available, most as part of the gastrointestinal or multiplex enteric panel assays targeting major diarrheal pathogens (<anchor id="ch0169s000000a0052"/><link linkend="ch0169s000000a0054">Table 5</link>). They offer high sensitivity and specificity and the ability to detect coinfections (<link linkend="ch0169s000000li0157">157</link>–<link linkend="ch0169s000000li0161">161</link>), and they may lead to more frequent detection of <emphasis>Cryptosporidium</emphasis>, which is not commonly ordered in tests of diarrheal pathogens (<link linkend="ch0169s000000li0162">162</link>–<link linkend="ch0169s000000li0164">164</link>). Other commercial molecular diagnostic kits include gastrointestinal parasite panels, and similar kits targeting only major diarrheal protozoa. The latter could be useful in targeted investigations of parasite-associated diarrhea cases in low- and middle-income countries (<link linkend="ch0169s000000li0165">165</link>–<link linkend="ch0169s000000li0171">171</link>). With reductions in price, the use of these panel assays in outbreak investigations and studies of disease burden is expected to increase in the near future. Many individual PCR kits are marketed for the detection of <emphasis>Cryptosporidium</emphasis> for research only. The utility of in-house multiplex quantitative PCRs in the assessment of causes of diarrhea has been demonstrated in the analysis of stool specimens from European soldiers deployed in Mali and reanalysis of stool specimens from the Global Enteric Multicenter Study (<link linkend="ch0169s000000li0172">172</link>–<link linkend="ch0169s000000li0174">174</link>).</para>
      <sect2 id="ch0169s0008s0001">
        <title>TYPING SYSTEMS</title>
        <anchor id="ch0169s000008a0002"/>
        <anchor id="ch0169s000000a0053"/>
        <para id="ch0169s000000p0037">Genotyping and subtyping have been used in characterizations of<emphasis>Cryptosporidium</emphasis> infections, especially in cryptosporidiosis surveillance and outbreak investigations. Although species-level identification is not needed for patient management, given that individual <emphasis>Cryptosporidium</emphasis> species have unique host ranges, identifying the <emphasis>Cryptosporidium</emphasis> species can provide insight into possible exposures and infection sources (<link linkend="ch0169s000000li0015">15</link>, <link linkend="ch0169s000000li0175">175</link>, <link linkend="ch0169s000000li0176">176</link>). Several small-subunit (SSU) rRNA gene-based, genus-specific PCR-restriction fragment length polymorphism-based genotyping or sequencing tools are available for the differentiation of various <emphasis>Cryptosporidium</emphasis> species (<link linkend="ch0169s000000li0177">177</link>, <link linkend="ch0169s000000li0178">178</link>). Other genotyping techniques are designed mostly for the differentiation of <emphasis>C. parvum</emphasis> and <emphasis>C. hominis</emphasis> and thus cannot detect and differentiate other <emphasis>Cryptosporidium</emphasis> spp. or genotypes (<link linkend="ch0169s000000li0015">15</link>, <link linkend="ch0169s000000li0175">175</link>). In recent years, SSU rRNA-based quantitative PCR (qPCR) assays have been increasingly used in genotyping <emphasis>Cryptosporidium</emphasis> spp. in humans (<link linkend="ch0169s000000li0155">155</link>, <link linkend="ch0169s000000li0179">179</link>–<link linkend="ch0169s000000li0185">185</link>). One SSU rRNA-based qPCR assay has a melting curve analysis developed for rapid genotyping of five common <emphasis>Cryptosporidium</emphasis> species in human specimens (<link linkend="ch0169s000000li0186">186</link>).</para>
        <table id="ch0169s000000t0005"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0169s000000a0054"/><link linkend="ch0169s000000a0052">TABLE 5</link></phrase></emphasis> Commercial enteric panel assays and other PCR assays for the detection of <emphasis>Cryptosporidium</emphasis> DNA in stool specimens
</title>
          
          <tgroup cols="4">
            <tbody>
              <row>
                <entry><phrase role="center">Product</phrase>
                </entry>
                <entry><phrase role="center">Pathogen targeted</phrase>
                </entry>
                <entry><phrase role="center">Manufacturer or distributor</phrase>
                </entry>
                <entry><phrase role="center">Regulatory status<superscript><emphasis><anchor id="ch0169s000000a0055"/><link linkend="ch0169s000000a0061">a</link></emphasis></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry>BioFire FilmArray gastrointestinal panel<superscript><emphasis><anchor id="ch0169s000000a0056"/><link linkend="ch0169s000000a0062">b</link></emphasis></superscript></entry>
                <entry>13 bacteria, 5 viruses, and 4 parasites</entry>
                <entry>bioMérieux SA, France,<ulink url="https://www.biomerieux-diagnostics.com/filmarrayr-gi-panel">https://www.biomerieux-diagnostics.com/filmarrayr-gi-panel</ulink></entry>
                <entry>FDA/CE</entry>
              </row>
              <row>
                <entry>BioCode Gastrointestinal Pathogen Panel</entry>
                <entry>10 bacteria, 3 viruses, and 3 parasites</entry>
                <entry>Applied Biocode, U.S.,<ulink url="https://www.apbiocode.com/index.htm">https://www.apbiocode.com/index.htm</ulink></entry>
                <entry>FDA/CE</entry>
              </row>
              <row>
                <entry>xTag Gastrointestinal Pathogen Panel<superscript><emphasis><link linkend="ch0169s000000a0062">b</link></emphasis></superscript></entry>
                <entry>9 bacteria, 3 viruses, and 3 parasites</entry>
                <entry>Luminex Molecular Diagnostics, Inc., U.S.,<ulink url="https://www.luminexcorp.com">https://www.luminexcorp.com</ulink></entry>
                <entry>FDA/CE</entry>
              </row>
              <row>
                <entry>EntericBio DX GI panel<superscript><emphasis><anchor id="ch0169s000000a0057"/><link linkend="ch0169s000000a0063">c</link></emphasis></superscript></entry>
                <entry>6 bacteria and 3 parasites</entry>
                <entry>Serosep, Ireland,<ulink url="http://www.serosep.com">http://www.serosep.com</ulink></entry>
                <entry>FDA/CE</entry>
              </row>
              <row>
                <entry>Allplex Gastrointestinal Panel Assay</entry>
                <entry>13 bacteria, 6 viruses, and 6 parasites</entry>
                <entry>Seegen, Korea, https://www.seegene.com/assays/gi</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>Faecal Pathogens A and M<superscript><emphasis><anchor id="ch0169s000000a0058"/><link linkend="ch0169s000000a0064">d</link></emphasis></superscript></entry>
                <entry>9 bacteria, 3 to 6 viruses, and 3 to 5 parasites</entry>
                <entry>AusDiagnostics Pty Ltd, Australia, http://www.ausdiagnostics.com</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>GastroFinder gastrointestinal panel</entry>
                <entry>9 bacteria, 5 viruses, and 4 parasites</entry>
                <entry>PathoFinder B.V., The Netherlands, https://www.pathofinder.com/</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>NanoCHIP gastrointestinal panel<superscript><emphasis><link linkend="ch0169s000000a0062">b</link></emphasis></superscript></entry>
                <entry>3 to 5 bacteria and 3 to 6 parasites</entry>
                <entry>Savyon Diagnostics, Israel, http://savyondiagnostics.com</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>QIAstat Gastrointestinal Panel</entry>
                <entry>15 bacteria, 5 viruses, and 4 parasites</entry>
                <entry>Qiagen, Netherlands https://qiastat-dx.com/row/</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>Novodiag Stool Parasites</entry>
                <entry>26 parasites</entry>
                <entry>Hologic, U.S., https://www.hologic.com/</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>BD MAX enteric parasite panel<superscript><emphasis><anchor id="ch0169s000000a0059"/><link linkend="ch0169s000000a0065">e</link></emphasis></superscript></entry>
                <entry>3 parasites</entry>
                <entry>Becton Dickinson, U.S., http://www.bd.com/en-us</entry>
                <entry>FDA/CE</entry>
              </row>
              <row>
                <entry>EasyScreen Enteric Protozoan Detection</entry>
                <entry>5 parasites</entry>
                <entry>Genetic Signatures Ltd., Australia https://geneticsignatures.com/au/</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>G-DiaPara<superscript><emphasis><anchor id="ch0169s000000a0060"/><link linkend="ch0169s000000a0066">f</link></emphasis></superscript></entry>
                <entry>3 parasites</entry>
                <entry>Diagenode Diagnostics, Belgium, https://www.diagenodediagnostics.com</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>FTD Stool Parasites<superscript><emphasis><link linkend="ch0169s000000a0062">b</link></emphasis></superscript></entry>
                <entry>3 parasites</entry>
                <entry>Launch Diagnostics, England https://www.launchdiagnostics.com/product-list/ftd-stool-parasites/</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>ParaGENIE Crypto-Micro Real-Time PCR</entry>
                <entry>3 parasites</entry>
                <entry>Ademtech, France, https://www.ademtech.com</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry>Viasure,<emphasis>Cryptosporidium</emphasis><superscript><emphasis><link linkend="ch0169s000000a0063">c</link></emphasis></superscript></entry>
                <entry><emphasis>Cryptosporidium</emphasis>
                </entry>
                <entry>CerTest Biotec, Spain, http://certest.es</entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry><emphasis>Cryptosporidium</emphasis> Tyzzer Kit<superscript><emphasis><link linkend="ch0169s000000a0063">c</link></emphasis></superscript></entry>
                <entry><emphasis>Cryptosporidium</emphasis>
                </entry>
                <entry>Liferiver, U.S.,<ulink url="http://www.liferiverbiotech.com">http://www.liferiverbiotech.com</ulink></entry>
                <entry>CE</entry>
              </row>
              <row>
                <entry><emphasis>Cryptosporidium</emphasis> Detection Kit</entry>
                <entry><emphasis>Cryptosporidium</emphasis>
                </entry>
                <entry>Norgen Biotek, Canada<ulink url="https://norgenbiotek.com">https://norgenbiotek.com</ulink></entry>
                <entry>CE</entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0169s000000a0061"/><link linkend="ch0169s000000a0055">a</link></emphasis></superscript>FDA, assay cleared by the U.S. Food and Drug Administration and commercially available in the United States; CE, assay cleared by Conformité Européenne.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0169s000000a0062"/><link linkend="ch0169s000000a0056">b</link></emphasis></superscript>Reported to detect <emphasis>Cryptosporidium</emphasis> spp.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0169s000000a0063"/><link linkend="ch0169s000000a0057">c</link></emphasis></superscript>Reported to detect <emphasis>Cryptosporidium.</emphasis></para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0169s000000a0064"/><link linkend="ch0169s000000a0058">d</link></emphasis></superscript>Reported to detect <emphasis>C. hominis, C. parvum, C. wrairi</emphasis>, and <emphasis>C. meleagridis</emphasis> but not <emphasis>C. felis, C. muris</emphasis>, or <emphasis>C. baileyi.</emphasis></para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0169s000000a0065"/><link linkend="ch0169s000000a0059">e</link></emphasis></superscript>Reported to detect <emphasis>C. hominis</emphasis> and <emphasis>C. parvum.</emphasis></para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0169s000000a0066"/><link linkend="ch0169s000000a0060">f</link></emphasis></superscript>Reported to detect <emphasis>C. parvum.</emphasis></para>
        <para id="ch0169s000000p0038">Several<emphasis>gp60</emphasis> (also known as <emphasis>gp40/15</emphasis>) gene-based subtyping tools have also been developed to characterize the diversity within <emphasis>C. parvum</emphasis> or <emphasis>C. hominis</emphasis> (<link linkend="ch0169s000000li0015">15</link>, <link linkend="ch0169s000000li0175">175</link>, <link linkend="ch0169s000000li0176">176</link>). The genetic heterogeneity in this gene is represented by sequence differences among subtype families and variations in the number of trinucleotide repeats (TCA, TCG, or TCT) in the beginning of the gene among subtypes within each subtype family. A nomenclature system is used in naming <emphasis>Cryptosporidium</emphasis> subtypes (<link linkend="ch0169s000000li0015">15</link>). The name of <emphasis>Cryptosporidium</emphasis> subtypes starts with the subtype family designation (Ia, Ib, Id, Ie, If, etc., for <emphasis>C. hominis</emphasis>; IIa, IIb, IIc, IId, etc., for <emphasis>C. parvum</emphasis>). This is followed by the number of TCA (represented by the letter A), TCG (represented by the letter G), or TCT (represented by the letter T) repeats. Thus, the name IbA10G2 indicates that the subtype belongs to the <emphasis>C. hominis</emphasis> Ib subtype family and has 10 copies of the TCA repeat and 2 copies of the TCG repeat in the trinucleotide repeat region of the gene. Subtyping tools are now routinely used in the investigation of cryptosporidiosis outbreaks (<link linkend="ch0169s000000li0025">25</link>, <link linkend="ch0169s000000li0048">48</link>, <link linkend="ch0169s000000li0058">58</link>, <link linkend="ch0169s000000li0074">74</link>, <link linkend="ch0169s000000li0093">93</link>, <link linkend="ch0169s000000li0111">111</link>, <link linkend="ch0169s000000li0187">187</link>–<link linkend="ch0169s000000li0194">194</link>). Subtyping <emphasis>C. parvum</emphasis> and <emphasis>C. hominis</emphasis> based on <emphasis>gp60</emphasis> sequence analysis is a key component of the current molecular surveillance system CryptoNet, which has facilitated the investigations of recent cryptosporidiosis outbreaks in the United States (<link linkend="ch0169s000000li0025">25</link>, <link linkend="ch0169s000000li0073">73</link>, <link linkend="ch0169s000000li0195">195</link>).</para>
        <anchor id="ch0169s000000a0067"/>
        <beginpage pagenum="2884"/>
        <para id="ch0169s000000p0039">High-resolution multilocus subtyping tools have been developed for<emphasis>C. parvum</emphasis> and <emphasis>C. hominis</emphasis> (<link linkend="ch0169s000000li0196">196</link>–<link linkend="ch0169s000000li0198">198</link>). With the recent development of next-generation sequence techniques and procedures for isolation and enrichment of pure <emphasis>Cryptosporidium</emphasis> DNA (<link linkend="ch0169s000000li0199">199</link>–<link linkend="ch0169s000000li0202">202</link>), whole-genome sequencing has been increasingly used in advanced characterizations of <emphasis>Cryptosporidium</emphasis> specimens (<link linkend="ch0169s000000li0203">203</link>–<link linkend="ch0169s000000li0208">208</link>). These new tools are needed in advanced typing of some dominant <emphasis>gp60</emphasis> subtypes, such as IbA10G2 of <emphasis>C. hominis</emphasis> and IIaA15G2R1 of <emphasis>C. parvum</emphasis> (<link linkend="ch0169s000000li0197">197</link>, <link linkend="ch0169s000000li0207">207</link>, <link linkend="ch0169s000000li0209">209</link>, <link linkend="ch0169s000000li0210">210</link>). Whole-genome sequencing of human-pathogenic <emphasis>Cryptosporidium</emphasis> spp. has been incorporated into CryptoNet.</para>
      </sect2>
      <sect2 id="ch0169s0008s0002">
        <title>ISOLATION PROCEDURES</title>
        <anchor id="ch0169s000008a0003"/>
        <anchor id="ch0169s000000a0068"/>
        <anchor id="ch0169s000000a0069"/>
        <para id="ch0169s000000p0040">The<emphasis>in vitro</emphasis> cultivation of <emphasis>Cryptosporidium</emphasis> spp. remains inefficient despite recent advances (<link linkend="ch0169s000000li0211">211</link>). The low parasite yields and oocyst production have limited the usefulness of parasite culture in the isolation and diagnosis of <emphasis>Cryptosporidium</emphasis> spp. As a result, isolation and cultivation of <emphasis>Cryptosporidium</emphasis> spp. are not practiced in clinical laboratories. <emphasis>In vitro</emphasis> cultivation of early <emphasis>Cryptosporidium</emphasis> developmental stages in several epithelial cell lines (HCT-8, MDBK, Caco-2, etc.) has been used widely in research studies to assess potential drugs and oocyst disinfection methods, and to characterize parasite development, differentiation, and biochemistry (<link linkend="ch0169s000000li0212">212</link>–<link linkend="ch0169s000000li0216">216</link>). The recent development of procedures for long-term maintenance of <emphasis>C. parvum</emphasis>, using cryopreservation for long-term storage of sporozoites and <emphasis>in vitro</emphasis> cultivation using stem cell-based enteroids, could promote the isolation of <emphasis>Cryptosporidium</emphasis> spp. for diagnosis and typing (<link linkend="ch0169s000000li0211">211</link>, <link linkend="ch0169s000000li0217">217</link>–<link linkend="ch0169s000000li0221">221</link>).</para>
      </sect2>
      <sect2 id="ch0169s0008s0003">
        <title>TREATMENT AND PREVENTION</title>
        <anchor id="ch0169s000008a0004"/>
        <anchor id="ch0169s000000a0070"/>
      </sect2>
    </sect1>
    <sect1 id="ch0169s0009">
      <title>Treatment</title>
      <anchor id="ch0169s000009a0001"/>
      <anchor id="ch0169s000000a0071"/>
      <para id="ch0169s000000p0041">Nitazoxanide is the only U.S. Food and Drug Administration-approved drug for the specific treatment of cryptosporidiosis in immunocompetent persons (<link linkend="ch0169s000000li0222">222</link>, <link linkend="ch0169s000000li0223">223</link>). Supportive oral or intravenous rehydration and antimotility are widely used whenever severe diarrhea is associated with cryptosporidiosis. Clinical trials have demonstrated that nitazoxanide can shorten clinical disease and reduce parasite loads (<link linkend="ch0169s000000li0224">224</link>). It has been used effectively in the treatment of clinical cryptosporidiosis in both industrialized nations and low- and middle-income countries (<link linkend="ch0169s000000li0225">225</link>, <link linkend="ch0169s000000li0226">226</link>). This drug, however, is not effective in the treatment of <emphasis>Cryptosporidium</emphasis> infections in immunodeficient patients (<link linkend="ch0169s000000li0227">227</link>). For this population, paromomycin, spiramycin, and clofazimine have been used in the treatment of some patients, but their efficacy remains unproven (<link linkend="ch0169s000000li0224">224</link>, <link linkend="ch0169s000000li0227">227</link>, <link linkend="ch0169s000000li0228">228</link>).</para>
      <para id="ch0169s000000p0042">In industrialized nations, the most effective treatment and prophylaxis for cryptosporidiosis in patients with HIV is the use of highly active antiretroviral therapy (HAART) (<link linkend="ch0169s000000li0222">222</link>). HAART is also an effective prevention for cryptosporidiosis in HIV-positive persons in low- and middle-income countries (<link linkend="ch0169s000000li0229">229</link>). It is believed that the eradication and prevention of the infection are related to the replenishment of CD4+ cells in treated persons and the antiparasitic activities of the protease inhibitors (such as indinavir, nelfinavir, and ritonavir) used in HAART (<link linkend="ch0169s000000li0230">230</link>, <link linkend="ch0169s000000li0231">231</link>). Relapse of cryptosporidiosis is common in patients with HIV who have stopped taking HAART (<link linkend="ch0169s000000li0222">222</link>). Recent reports have shown that cryptosporidiosis is still common in HIV-positive patients receiving HAART in low- and middle-income countries, although at lower frequencies than those generally reported in untreated HIV patients (<link linkend="ch0169s000000li0031">31</link>, <link linkend="ch0169s000000li0039">39</link>, <link linkend="ch0169s000000li0049">49</link>, <link linkend="ch0169s000000li0232">232</link>–<link linkend="ch0169s000000li0234">234</link>).</para>
      <para id="ch0169s000000p0043">The development of effective therapy against cryptosporidiosis has received increased attention after the recent identification of cryptosporidiosis as a primary cause of moderate to severe diarrhea and diarrhea-associated mortality in young children in low- and middle-income countries (<link linkend="ch0169s000000li0223">223</link>, <link linkend="ch0169s000000li0235">235</link>–<link linkend="ch0169s000000li0238">238</link>). With improved understanding of <emphasis>Cryptosporidium</emphasis> metabolism and availability of new research tools (<link linkend="ch0169s000000li0239">239</link>–<link linkend="ch0169s000000li0242">242</link>), several <emphasis>Cryptosporidium</emphasis> targets have shown promise in drug development, including calcium-dependent protein kinases, phosphatidylinositol-4-kinase and other kinases, and lactate dehydrogenase. Several selective inhibitors of these <emphasis>Cryptosporidium</emphasis> enzymes have been identified in a series of recent studies (<link linkend="ch0169s000000li0215">215</link>, <link linkend="ch0169s000000li0227">227</link>, <link linkend="ch0169s000000li0243">243</link>–<link linkend="ch0169s000000li0254">254</link>). Several groups of existing drugs for other pathogens have been identified as potential repurposed drugs for the treatment of cryptosporidiosis (<link linkend="ch0169s000000li0223">223</link>, <link linkend="ch0169s000000li0236">236</link>, <link linkend="ch0169s000000li0255">255</link>).</para>
    </sect1>
    <sect1 id="ch0169s0010">
      <title>Prevention</title>
      <anchor id="ch0169s000010a0001"/>
      <anchor id="ch0169s000000a0072"/>
      <para id="ch0169s000000p0044">As for any pathogens that are transmitted by the fecal-oral route, good hygiene is the key in preventing the acquisition of<emphasis>Cryptosporidium</emphasis> infection (<link linkend="ch0169s000000li0019">19</link>, <link linkend="ch0169s000000li0256">256</link>–<link linkend="ch0169s000000li0259">259</link>). In particular, immunosuppressed persons should take necessary precautions in preventing the occurrence of cryptosporidiosis (<link linkend="ch0169s000000li0260">260</link>). This includes washing hands before preparing food and after going to the bathroom, changing diapers, and coming into contact with calves, lambs, goat kids, pets, or soil (including gardening); refraining from drinking water from lakes and rivers, swallowing water in recreational activities, and consuming unpasteurized milk, milk products, and juices; and following safe-sex practices (avoiding oral-anal contact). During cryptosporidiosis outbreaks or when a community advisory to boil water is issued, individuals should boil water for 1 min to kill the parasite or use a tap water filter capable of removing particles less than 1 µm in diameter. Immunosuppressed persons also should avoid eating raw shellfish and should not eat uncooked vegetable salads and unpeeled fruits when traveling to low- and middle-income countries (<link linkend="ch0169s000000li0260">260</link>). As cryptosporidiosis is a zoonotic disease, One Health measures have been advocated in its prevention and control (<link linkend="ch0169s000000li0024">24</link>, <link linkend="ch0169s000000li0261">261</link>).</para>
      <sect2 id="ch0169s0010s0001">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0169s000010a0002"/>
        <anchor id="ch0169s000000a0073"/>
        <para id="ch0169s000000p0045">Cryptosporidiosis is a notifiable disease in most states in the United States and in some other industrialized countries, although only about 1.4% of actual cases are diagnosed in the United States (<link linkend="ch0169s000000li0022">22</link>, <link linkend="ch0169s000000li0023">23</link>). Thus, the detection of the pathogen in stools or tissues should be reported to the local health department in addition to the physician. Because most routine diagnostic tests cannot differentiate <emphasis>Cryptosporidium</emphasis> species, the detection of <emphasis>Cryptosporidium</emphasis> oocysts or antigens in stools or other specimens should be reported as <emphasis>Cryptosporidium</emphasis> positive without referring to the nature of species involved. As asymptomatic carriage of oocysts can persist for some time, attempts have been made to establish quantitative cutoff values for association of test positivity with diarrhea (<link linkend="ch0169s000000li0262">262</link>). In one study, such values were reported to be 2.3 × 10<superscript>5</superscript> DNA copies per g of wet stool for qPCR and 725 oocysts per g for a quantitative DFA (<link linkend="ch0169s000000li0130">130</link>). These values, however, were established based on data from children in a low-income setting; cutoff values could be different for other patient populations in developed countries due to differences in anti-<emphasis>Cryptosporidium</emphasis> immunity.</para>
        <para id="ch0169s000000p0046">From a public health point of view, the reporting of significant numbers of cases above background levels in industrialized nations indicates the likely occurrence of outbreaks of cryptosporidiosis or false positivity of diagnostic kits (<link linkend="ch0169s000000li0154">154</link>, <link linkend="ch0169s000000li0263">263</link>, <link linkend="ch0169s000000li0264">264</link>). In situations like this, it is crucial to have the test results verified with a confirmatory test such as DFA, microscopy with special stains, or PCR and to report them to the state or local public health department. The inclusion of both positive and negative controls in each test run and stringent adherence to the recommended procedures will reduce the occurrence of test errors. In the United States, patients positive for <emphasis>Cryptosporidium</emphasis> by immunochromatographic assay-based rapid tests are considered by the Council of State and Territorial Epidemiologists as probable cryptosporidiosis cases. The diagnostic result requires the confirmation by a second test such as DFA, microscopy with modified acid-fast or other stains, EIA, or PCR. In some states such as Minnesota and Tennessee, state regulations require that all <emphasis>Cryptosporidium</emphasis>-positive specimens be submitted to state public health laboratories for confirmatory testing and molecular characterizations.</para>
        <anchor id="ch0169s000000a0074"/>
        <beginpage pagenum="2886"/>
        <para id="ch0169s000000p0047"><emphasis>This work was supported in part by National Natural Science Foundation of China (no. 32030109). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication</emphasis>.</para>
      </sect2>
      <sect2 id="ch0169s0010s0002">
        <title>REFERENCES</title>
        <anchor id="ch0169s000010a0003"/>
        <anchor id="ch0169s000000a0075"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0169s000000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Checkley W, White AC Jr, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, Fayer R, Griffiths JK, Guerrant RL, Hedstrom L, Huston CD, Kotloff KL, Kang G, Mead JR, Miller M, Petri WA Jr, Priest JW, Roos DS, Striepen B, Thompson RC, Ward HD, Van Voorhis WA, Xiao L, Zhu G, Houpt ER.</emphasis> 2015. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for <citetitle><emphasis>Cryptosporidium. Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>85–94.</para>
          </listitem>
          <listitem id="ch0169s000000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acácio S, Biswas K, O’Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM.</emphasis> 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">382:</emphasis>209–222.</para>
          </listitem>
          <listitem id="ch0169s000000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Platts-Mills JA, Babji S, Bodhidatta L, Gratz J, Haque R, Havt A, McCormick BJ, McGrath M, Olortegui MP, Samie A, Shakoor S, Mondal D, Lima IF, Hariraju D, Rayamajhi BB, Qureshi S, Kabir F, Yori PP, Mufamadi B, Amour C, Carreon JD, Richard SA, Lang D, Bessong P, Mduma E, Ahmed T, Lima AA, Mason CJ, Zaidi AK, Bhutta ZA, Kosek M, Guerrant RL, Gottlieb M, Miller M, Kang G, Houpt ER, MAL-ED Network Investigators.</emphasis> 2015. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). <citetitle><emphasis>Lancet Glob Health</emphasis></citetitle> <emphasis role="strong">3:</emphasis>e564–e575.</para>
          </listitem>
          <listitem id="ch0169s000000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">GBD Diarrhoeal Diseases Collaborators.</emphasis> 2017. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>909–948.</para>
          </listitem>
          <listitem id="ch0169s000000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Khalil IA, Troeger C, Rao PC, Blacker BF, Brown A, Brewer TG, Colombara DV, De Hostos EL, Engmann C, Guerrant RL, Haque R, Houpt ER, Kang G, Korpe PS, Kotloff KL, Lima AAM, Petri WA Jr, Platts-Mills JA, Shoultz DA, Forouzanfar MH, Hay SI, Reiner RC Jr, Mokdad AH.</emphasis> 2018. Morbidity, mortality, and long-term consequences associated with diarrhoea from <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection in children younger than 5 years: a meta-analyses study. <citetitle><emphasis>Lancet Glob Health</emphasis></citetitle> <emphasis role="strong">6:</emphasis>e758–e768.</para>
          </listitem>
          <listitem id="ch0169s000000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Zahedi A, Ryan U.</emphasis> 2020. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle>—an update with an emphasis on foodborne and waterborne transmission. <citetitle><emphasis>Res Vet Sci</emphasis></citetitle> <emphasis role="strong">132:</emphasis>500–512.</para>
          </listitem>
          <listitem id="ch0169s000000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Rafferty ER, Schurer JM, Arndt MB, Choy RKM, de Hostos EL, Shoultz D, Farag M.</emphasis> 2017. Pediatric cryptosporidiosis: an evaluation of health care and societal costs in Peru, Bangladesh and Kenya. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0182820.</para>
          </listitem>
          <listitem id="ch0169s000000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Collier SA, Stockman LJ, Hicks LA, Garrison LE, Zhou FJ, Beach MJ.</emphasis> 2012. Direct healthcare costs of selected diseases primarily or partially transmitted by water. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">140:</emphasis>2003–2013.</para>
          </listitem>
          <listitem id="ch0169s000000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Chyzheuskaya A, Cormican M, Srivinas R, O’Donovan D, Prendergast M, O’Donoghue C, Morris D.</emphasis> 2017. Economic assessment of waterborne outbreak of cryptosporidiosis. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>1650–1656.</para>
          </listitem>
          <listitem id="ch0169s000000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Dumaine JE, Tandel J, Striepen B.</emphasis> 2020. <citetitle><emphasis>Cryptosporidium parvum. Trends Parasitol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>485–486.</para>
          </listitem>
          <listitem id="ch0169s000000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Ryan UM, Feng Y, Fayer R, Xiao L.</emphasis> 2021. Taxonomy and molecular epidemiology of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> and <citetitle><emphasis>Giardia</emphasis></citetitle>—a 50 year perspective (1971–2021). <citetitle><emphasis>Int J Parasitol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1099–1119.</para>
          </listitem>
          <listitem id="ch0169s000000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Xiao L, Feng Y.</emphasis> 2008. Zoonotic cryptosporidiosis. <citetitle><emphasis>FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>309–323.</para>
          </listitem>
          <listitem id="ch0169s000000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Sponseller JK, Griffiths JK, Tzipori S.</emphasis> 2014. The evolution of respiratory cryptosporidiosis: evidence for transmission by inhalation. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">27:</emphasis>575–586.</para>
          </listitem>
          <listitem id="ch0169s000000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Ryan U, Paparini A, Monis P, Hijjawi N.</emphasis> 2016. It’s official—<citetitle><emphasis>Cryptosporidium</emphasis></citetitle> is a gregarine: what are the implications for the water industry? <citetitle><emphasis>Water Res</emphasis></citetitle> <emphasis role="strong">105:</emphasis>305–313.</para>
          </listitem>
          <listitem id="ch0169s000000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Xiao L, Feng Y.</emphasis> 2017. Molecular epidemiologic tools for waterborne pathogens <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. and <citetitle><emphasis>Giardia duodenalis. Food Waterborne Parasitol</emphasis></citetitle> <emphasis role="strong">8-9:</emphasis>14–32.</para>
          </listitem>
          <listitem id="ch0169s000000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Ryan U, Zahedi A, Feng Y, Xiao L.</emphasis> 2021. An update on zoonotic <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species and genotypes in humans. <citetitle><emphasis>Animals (Basel)</emphasis></citetitle> <emphasis role="strong">11:</emphasis>3307.</para>
          </listitem>
          <listitem id="ch0169s000000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Feng Y, Ryan UM, Xiao L.</emphasis> 2018. Genetic diversity and population structure of <citetitle><emphasis>Cryptosporidium. Trends Parasitol</emphasis></citetitle> <emphasis role="strong">34:</emphasis>997–1011.</para>
          </listitem>
          <listitem id="ch0169s000000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Lebbad M, Winiecka-Krusnell J, Stensvold CR, Beser J.</emphasis> 2021. High diversity of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species and subtypes identified in cryptosporidiosis acquired in Sweden and abroad. <citetitle><emphasis>Pathogens</emphasis></citetitle> <emphasis role="strong">10:</emphasis>523.</para>
          </listitem>
          <listitem id="ch0169s000000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Yang X, Guo Y, Xiao L, Feng Y.</emphasis> 2021. Molecular epidemiology of human cryptosporidiosis in low- and middle-income countries. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">34:</emphasis>e00087–e00019.</para>
          </listitem>
          <listitem id="ch0169s000000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Garcia-R JC, Pita AB, Velathanthiri N, French NP, Hayman DTS.</emphasis> 2020. Species and genotypes causing human cryptosporidiosis in New Zealand. <citetitle><emphasis>Parasitol Res</emphasis></citetitle> <emphasis role="strong">119:</emphasis>2317–2326.</para>
          </listitem>
          <listitem id="ch0169s000000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Painter JE, Gargano JW, Yoder JS, Collier SA, Hlavsa MC.</emphasis> 2016. Evolving epidemiology of reported cryptosporidiosis cases in the United States, 1995–2012. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">144:</emphasis>1792–1802.</para>
          </listitem>
          <listitem id="ch0169s000000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM.</emphasis> 2011. Foodborne illness acquired in the United States—major pathogens. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>7–15.</para>
          </listitem>
          <listitem id="ch0169s000000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Cacciò SM, Chalmers RM.</emphasis> 2016. Human cryptosporidiosis in Europe. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">22:</emphasis>471–480.</para>
          </listitem>
          <listitem id="ch0169s000000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Ryan U, Zahedi A, Paparini A.</emphasis> 2016. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> in humans and animals—a One Health approach to prophylaxis. <citetitle><emphasis>Parasite Immunol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>535–547.</para>
          </listitem>
          <listitem id="ch0169s000000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Hlavsa MC, Roellig DM, Seabolt MH, Kahler AM, Murphy JL, McKitt TK, Geeter EF, Dawsey R, Davidson SL, Kim TN, Tucker TH, Iverson SA, Garrett B, Fowle N, Collins J, Epperson G, Zusy S, Weiss JR, Komatsu K, Rodriguez E, Patterson JG, Sunenshine R, Taylor B, Cibulskas K, Denny L, Omura K, Tsorin B, Fullerton KE, Xiao L.</emphasis> 2017. Using molecular characterization to support investigations of aquatic facility-associated outbreaks of cryptosporidiosis—Alabama, Arizona, and Ohio, 2016. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">66:</emphasis>493–497.</para>
          </listitem>
          <listitem id="ch0169s000000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Squire SA, Ryan U.</emphasis> 2017. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> and <citetitle><emphasis>Giardia</emphasis></citetitle> in Africa: current and future challenges. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">10:</emphasis>195.</para>
          </listitem>
          <listitem id="ch0169s000000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Kattula D, Jeyavelu N, Prabhakaran AD, Premkumar PS, Velusamy V, Venugopal S, Geetha JC, Lazarus RP, Das P, Nithyanandhan K, Gunasekaran C, Muliyil J, Sarkar R, Wanke C, Ajjampur SS, Babji S, Naumova EN, Ward HD, Kang G.</emphasis> 2017. Natural history of cryptosporidiosis in a birth cohort in Southern India. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">64:</emphasis>347–354.</para>
          </listitem>
          <listitem id="ch0169s000000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Mor SM, DeMaria A Jr, Griffiths JK, Naumova EN.</emphasis> 2009. Cryptosporidiosis in the elderly population of the United States. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">48:</emphasis>698–705.</para>
          </listitem>
          <listitem id="ch0169s000000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Benedict KM, Collier SA, Marder EP, Hlavsa MC, Fullerton KE, Yoder JS.</emphasis> 2019. Case-case analyses of cryptosporidiosis and giardiasis using routine national surveillance data in the United States—2005–2015. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">147:</emphasis>e178.</para>
          </listitem>
          <listitem id="ch0169s000000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Lanternier F, Amazzough K, Favennec L, Mamzer-Bruneel MF, Abdoul H, Tourret J, Decramer S, Zuber J, Scemla A, Legendre C, Lortholary O, Bougnoux ME, ANOFEL Cryptosporidium National Network and Transplant Cryptosporidium Study Group.</emphasis> 2017. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. infection in solid organ transplantation: the nationwide “TRANSCRYPTO” study. <citetitle><emphasis>Transplantation</emphasis></citetitle> <emphasis role="strong">101:</emphasis>826–830.</para>
          </listitem>
          <listitem id="ch0169s000000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Wang RJ, Li JQ, Chen YC, Zhang LX, Xiao LH.</emphasis> 2018. Widespread occurrence of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infections in patients with HIV/AIDS: epidemiology, clinical feature, diagnosis, and therapy. <citetitle><emphasis>Acta Trop</emphasis></citetitle> <emphasis role="strong">187:</emphasis>257–263.</para>
          </listitem>
          <listitem id="ch0169s000000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Kalantari N, Gorgani-Firouzjaee T, Ghaffari S, Bayani M, Ghaffari T, Chehrazi M.</emphasis> 2020. Association between <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection and cancer: a systematic review and meta-analysis. <citetitle><emphasis>Parasitol Int</emphasis></citetitle> <emphasis role="strong">74:</emphasis>101979.</para>
          </listitem>
          <listitem id="ch0169s000000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Berahmat R, Mahami-Oskouei M, Rezamand A, Spotin A, Aminisani N, Ghoyounchi R, Madadi S.</emphasis> 2017. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection in children with cancer undergoing chemotherapy: how important is the prevention of opportunistic parasitic infections in patients with malignancies? <citetitle><emphasis>Parasitol Res</emphasis></citetitle> <emphasis role="strong">116:</emphasis>2507–2515.</para>
          </listitem>
          <listitem id="ch0169s000000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Zueter AM, Hijjawi NS, Hamadeneh KN, Al-Sheyab MM, Hatamleh AM.</emphasis> 2019. Cryptosporidiosis among hemodialysis patients in Jordan: first preliminary screening surveillance. <citetitle><emphasis>Trop Med Infect Dis</emphasis></citetitle> <emphasis role="strong">4:</emphasis>131.</para>
          </listitem>
          <listitem id="ch0169s000000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">El-Kady AM, Fahmi Y, Tolba M, Hashim AA, Hassan AA.</emphasis> 2018. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection in chronic kidney disease patients undergoing hemodialysis in Egypt. <citetitle><emphasis>J Parasit Dis</emphasis></citetitle> <emphasis role="strong">42:</emphasis>630–635.</para>
          </listitem>
          <listitem id="ch0169s000000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Mohaghegh MA, Hejazi SH, Ghomashlooyan M, Kalani H, Mirzaei F, Azami M.</emphasis> 2017. Prevalence and clinical features of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection in hemodialysis patients. <citetitle><emphasis>Gastroenterol Hepatol Bed Bench</emphasis></citetitle> <emphasis role="strong">10:</emphasis>137–142.</para>
          </listitem>
          <listitem id="ch0169s000000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">McAteer J, Jernigan S, Mao C, Gonzalez MD, Watson RJ, Liverman R, Tobin-D Angelo M, Dishman M H, Shane A, Yildirim I.</emphasis> 2020. Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp. <citetitle><emphasis>Pediatr Transplant</emphasis></citetitle> <emphasis role="strong">24:</emphasis>e13649.</para>
          </listitem>
          <listitem id="ch0169s000000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Costa D, Razakandrainibe R, Sautour M, Valot S, Basmaciyan L, Gargala G, Lemeteil D, Favennec L, Dalle F, French National Network on Surveillance of Human Cryptosporidiosis.</emphasis> 2018. Human cryptosporidiosis in immunodeficient patients in France (2015-2017). <citetitle><emphasis>Exp Parasitol</emphasis></citetitle> <emphasis role="strong">192:</emphasis>108–112.</para>
          </listitem>
          <listitem id="ch0169s000000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Ahmadpour E, Safarpour H, Xiao L, Zarean M, Hatam-Nahavandi K, Barac A, Picot S, Rahimi MT, Rubino S, Mahami-Oskouei M, Spotin A, Nami S, Baghi HB.</emphasis> 2020. Cryptosporidiosis in HIV-positive patients and related risk factors: a systematic review and meta-analysis. <citetitle><emphasis>Parasite</emphasis></citetitle> <emphasis role="strong">27:</emphasis>27.</para>
          </listitem>
          <listitem id="ch0169s000000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Nic Lochlainn LM, Sane J, Schimmer B, Mooij S, Roelfsema J, van Pelt W, Kortbeek T.</emphasis> 2019. Risk factors for sporadic cryptosporidiosis in the Netherlands: analysis of a 3-year population based case-control study coupled with genotyping, 2013–2016. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">219:</emphasis>1121–1129.</para>
          </listitem>
          <listitem id="ch0169s000000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Hellard M, Hocking J, Willis J, Dore G, Fairley C.</emphasis> 2003. Risk factors leading to <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection in men who have sex with men. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">79:</emphasis>412–414.</para>
          </listitem>
          <listitem id="ch0169s000000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Roy SL, DeLong SM, Stenzel SA, Shiferaw B, Roberts JM, Khalakdina A, Marcus R, Segler SD, Shah DD, Thomas S, Vugia DJ, Zansky SM, Dietz V, Beach MJ, Emerging Infections Program FoodNet Working Group.</emphasis> 2004. Risk factors for sporadic cryptosporidiosis among immunocompetent persons in the United States from 1999 to 2001. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>2944–2951.</para>
          </listitem>
          <listitem id="ch0169s000000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Hunter PR, Hughes S, Woodhouse S, Syed Q, Verlander NQ, Chalmers RM, Morgan K, Nichols G, Beeching N, Osborn K.</emphasis> 2004. Sporadic cryptosporidiosis case-control study with genotyping. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1241–1249.</para>
          </listitem>
          <listitem id="ch0169s000000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Pollock KG, Ternent HE, Mellor DJ, Chalmers RM, Smith HV, Ramsay CN, Innocent GT.</emphasis> 2010. Spatial and temporal epidemiology of sporadic human cryptosporidiosis in Scotland. <citetitle><emphasis>Zoonoses Public Health</emphasis></citetitle> <emphasis role="strong">57:</emphasis>487–492.</para>
          </listitem>
          <listitem id="ch0169s000000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Lake IR, Harrison FC, Chalmers RM, Bentham G, Nichols G, Hunter PR, Kovats RS, Grundy C.</emphasis> 2007. Case-control study of environmental and social factors influencing cryptosporidiosis. <citetitle><emphasis>Eur J Epidemiol</emphasis></citetitle> <emphasis role="strong">22:</emphasis>805–811.</para>
          </listitem>
          <listitem id="ch0169s000000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Snel SJ, Baker MG, Venugopal K.</emphasis> 2009. The epidemiology of cryptosporidiosis in New Zealand, 1997-2006. <citetitle><emphasis>N Z Med J</emphasis></citetitle> <emphasis role="strong">122:</emphasis>47–61.</para>
          </listitem>
          <listitem id="ch0169s000000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Yoder JS, Beach MJ.</emphasis> 2010. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> surveillance and risk factors in the United States. <citetitle><emphasis>Exp Parasitol</emphasis></citetitle> <emphasis role="strong">124:</emphasis>31–39.</para>
          </listitem>
          <listitem id="ch0169s000000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Loeck BK, Pedati C, Iwen PC, McCutchen E, Roellig DM, Hlavsa MC, Fullerton K, Safranek T, Carlson AV.</emphasis> 2020. Genotyping and subtyping <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> to identify risk factors and transmission patterns—Nebraska, 2015–2017. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">69:</emphasis>335–338.</para>
          </listitem>
          <listitem id="ch0169s000000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Adamu H, Petros B, Zhang G, Kassa H, Amer S, Ye J, Feng Y, Xiao L.</emphasis> 2014. Distribution and clinical manifestations of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species and subtypes in HIV/AIDS patients in Ethiopia. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e2831.</para>
          </listitem>
          <listitem id="ch0169s000000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Wang L, Zhang H, Zhao X, Zhang L, Zhang G, Guo M, Liu L, Feng Y, Xiao L.</emphasis> 2013. Zoonotic <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species and <citetitle><emphasis>Enterocytozoon bieneusi</emphasis></citetitle> genotypes in HIV-positive patients on antiretroviral therapy. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>557–563.</para>
          </listitem>
          <listitem id="ch0169s000000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Akinbo FO, Okaka CE, Omoregie R, Dearen T, Leon ET, Xiao L.</emphasis> 2012. Molecular epidemiologic characterization of <citetitle><emphasis>Enterocytozoon bieneusi</emphasis></citetitle> in HIV-infected persons in Benin City, Nigeria. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">86:</emphasis>441–445.</para>
          </listitem>
          <listitem id="ch0169s000000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Yang Y, Zhou YB, Xiao PL, Shi Y, Chen Y, Liang S, Yihuo WL, Song XX, Jiang QW.</emphasis> 2017. Prevalence of and risk factors associated with <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection in an underdeveloped rural community of southwest China. <citetitle><emphasis>Infect Dis Poverty</emphasis></citetitle> <emphasis role="strong">6:</emphasis>2.</para>
          </listitem>
          <listitem id="ch0169s000000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Quihui-Cota L, Morales-Figueroa GG, Javalera-Duarte A, Ponce-Martínez JA, Valbuena-Gregorio E, López-Mata MA.</emphasis> 2017. Prevalence and associated risk factors for <citetitle><emphasis>Giardia</emphasis></citetitle> and <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infections among children of northwest Mexico: a cross-sectional study. <citetitle><emphasis>BMC Public Health</emphasis></citetitle> <emphasis role="strong">17:</emphasis>852.</para>
          </listitem>
          <listitem id="ch0169s000000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">de Lucio A, Bailo B, Aguilera M, Cardona GA, Fernández-Crespo JC, Carmena D.</emphasis> 2017. No molecular epidemiological evidence supporting household transmission of zoonotic <citetitle><emphasis>Giardia duodenalis</emphasis></citetitle> and <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. from pet dogs and cats in the province of Álava, Northern Spain. <citetitle><emphasis>Acta Trop</emphasis></citetitle> <emphasis role="strong">170:</emphasis>48–56.</para>
          </listitem>
          <listitem id="ch0169s000000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Beser J, Toresson L, Eitrem R, Troell K, Winiecka-Krusnell J, Lebbad M.</emphasis> 2015. Possible zoonotic transmission of <citetitle><emphasis>Cryptosporidium felis</emphasis></citetitle> in a household. <citetitle><emphasis>Infect Ecol Epidemiol</emphasis></citetitle> <emphasis role="strong">5:</emphasis>28463.</para>
          </listitem>
          <listitem id="ch0169s000000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Xiao L, Cama VA, Cabrera L, Ortega Y, Pearson J, Gilman RH.</emphasis> 2007. Possible transmission of <citetitle><emphasis>Cryptosporidium canis</emphasis></citetitle> among children and a dog in a household. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2014–2016.</para>
          </listitem>
          <listitem id="ch0169s000000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Li J, Ryan U, Guo Y, Feng Y, Xiao L.</emphasis> 2021. Advances in molecular epidemiology of cryptosporidiosis in dogs and cats. <citetitle><emphasis>Int J Parasitol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>787–795.</para>
          </listitem>
          <listitem id="ch0169s000000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Costa D, Razakandrainibe R, Valot S, Vannier M, Sautour M, Basmaciyan L, Gargala G, Viller V, Lemeteil D, Ballet JJ, Dalle F, Favennec L, French National Network on Surveillance of Human Cryptosporidiosis.</emphasis> 2020. Epidemiology of cryptosporidiosis in France from 2017 to 2019. <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">8:</emphasis>1358.</para>
          </listitem>
          <listitem id="ch0169s000000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Elwin K, Hadfield SJ, Robinson G, Chalmers RM.</emphasis> 2012. The epidemiology of sporadic human infections with unusual cryptosporidia detected during routine typing in England and Wales, 2000–2008. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">140:</emphasis>673–683.</para>
          </listitem>
          <listitem id="ch0169s000000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Nazemalhosseini-Mojarad E, Feng Y, Xiao L.</emphasis> 2012. The importance of subtype analysis of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. in epidemiological investigations of human cryptosporidiosis in Iran and other Mideast countries. <citetitle><emphasis>Gastroenterol Hepatol Bed Bench</emphasis></citetitle> <emphasis role="strong">5:</emphasis>67–70.</para>
          </listitem>
          <listitem id="ch0169s000000li0061" role="bibliographyEntry">
            <anchor id="ch0169s000000a0077"/>
            <para>61.<emphasis role="strong">Iqbal J, Khalid N, Hira PR.</emphasis> 2011. Cryptosporidiosis in Kuwaiti children: association of clinical characteristics with <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species and subtypes. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>647–652.</para>
          </listitem>
          <listitem id="ch0169s000000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Alyousefi NA, Mahdy MA, Lim YA, Xiao L, Mahmud R.</emphasis> 2013. First molecular characterization of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> in Yemen. <citetitle><emphasis>Parasitology</emphasis></citetitle> <emphasis role="strong">140:</emphasis>729–734.</para>
          </listitem>
          <listitem id="ch0169s000000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Boughattas S, Behnke JM, Al-Sadeq D, Ismail A, Abu-Madi M.</emphasis> 2019. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp., prevalence, molecular characterisation and socio-demographic risk factors among immigrants in Qatar. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>e0007750.</para>
          </listitem>
          <listitem id="ch0169s000000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Guo Y, Li N, Ryan U, Feng Y, Xiao L.</emphasis> 2021. Small ruminants and zoonotic cryptosporidiosis. <citetitle><emphasis>Parasitol Res</emphasis></citetitle> <emphasis role="strong">120:</emphasis>4189–4198.</para>
          </listitem>
          <listitem id="ch0169s000000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Chalmers RM, Elwin K, Thomas AL, Guy EC, Mason B.</emphasis> 2009. Long-term <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> typing reveals the aetiology and species-specific epidemiology of human cryptosporidiosis in England and Wales, 2000 to 2003. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">14:</emphasis>19086.</para>
          </listitem>
          <listitem id="ch0169s000000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Painter JE, Hlavsa MC, Collier SA, Xiao L, Yoder JS, Centers for Disease Control and Prevention.</emphasis> 2015. Cryptosporidiosis surveillance—United States, 2011–2012. <citetitle><emphasis>MMWR Suppl</emphasis></citetitle> <emphasis role="strong">64</emphasis>(<link linkend="ch0169s000000li0003">3</link>)<emphasis role="strong">:</emphasis>1–14.</para>
          </listitem>
          <listitem id="ch0169s000000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Hlavsa MC, Aluko SK, Miller AD, Person J, Gerdes ME, Lee S, Laco JP, Hannapel EJ, Hill VR.</emphasis> 2021. Outbreaks associated with treated recreational water—United States, 2015–2019. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">70:</emphasis>733–738.</para>
          </listitem>
          <listitem id="ch0169s000000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Sarkar R, Ajjampur SS, Prabakaran AD, Geetha JC, Sowmyanarayanan TV, Kane A, Duara J, Muliyil J, Balraj V, Naumova EN, Ward H, Kang G.</emphasis> 2013. Cryptosporidiosis among children in an endemic semiurban community in southern India: does a protected drinking water source decrease infection? <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">57:</emphasis>398–406.</para>
          </listitem>
          <listitem id="ch0169s000000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Chalmers RM.</emphasis> 2012. Waterborne outbreaks of cryptosporidiosis. <citetitle><emphasis>Ann Ist Super Sanita</emphasis></citetitle> <emphasis role="strong">48:</emphasis>429–446.</para>
          </listitem>
          <listitem id="ch0169s000000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Gharpure R, Perez A, Miller AD, Wikswo ME, Silver R, Hlavsa MC.</emphasis> 2019. Cryptosporidiosis outbreaks—United States, 2009–2017. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">68:</emphasis>568–572.</para>
          </listitem>
          <listitem id="ch0169s000000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Efstratiou A, Ongerth JE, Karanis P.</emphasis> 2017. Waterborne transmission of protozoan parasites: review of worldwide outbreaks—an update 2011–2016. <citetitle><emphasis>Water Res</emphasis></citetitle> <emphasis role="strong">114:</emphasis>14–22.</para>
          </listitem>
          <listitem id="ch0169s000000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Hlavsa MC, Roberts VA, Anderson AR, Hill VR, Kahler AM, Orr M, Garrison LE, Hicks LA, Newton A, Hilborn ED, Wade TJ, Beach MJ, Yoder JS, CDC.</emphasis> 2011. Surveillance for waterborne disease outbreaks and other health events associated with recreational water—United States, 2007–2008. <citetitle><emphasis>MMWR Surveill Summ</emphasis></citetitle> <emphasis role="strong">60:</emphasis>1–32.</para>
          </listitem>
          <listitem id="ch0169s000000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Hlavsa MC, Roberts VA, Kahler AM, Hilborn ED, Mecher TR, Beach MJ, Wade TJ, Yoder JS, Centers for Disease Control and Prevention (CDC).</emphasis> 2015. Outbreaks of illness associated with recreational water—United States, 2011–2012. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">64:</emphasis>668–672.</para>
          </listitem>
          <listitem id="ch0169s000000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Chalmers RM, Robinson G, Elwin K, Elson R.</emphasis> 2019. Analysis of the <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. and gp60 subtypes linked to human outbreaks of cryptosporidiosis in England and Wales, 2009 to 2017. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">12:</emphasis>95.</para>
          </listitem>
          <listitem id="ch0169s000000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Puleston RL, Mallaghan CM, Modha DE, Hunter PR, Nguyen-Van-Tam JS, Regan CM, Nichols GL, Chalmers RM.</emphasis> 2014. The first recorded outbreak of cryptosporidiosis due to <citetitle><emphasis>Cryptosporidium cuniculus</emphasis></citetitle> (formerly rabbit genotype), following a water quality incident. <citetitle><emphasis>J Water Health</emphasis></citetitle> <emphasis role="strong">12:</emphasis>41–50.</para>
          </listitem>
          <listitem id="ch0169s000000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Asano Y, Karasudani T, Okuyama M, Takami S, Oseto M, Inouye H, Yamamoto K, Aokage J, Saiki N, Fujiwara M, Shiraishi M, Uchida K, Saiki H, Suzuki M, Yamamoto T, Udaka M, Kan K, Matsuura S, Kimura M.</emphasis> 2006. An outbreak of gastroenteritis associated with <citetitle><emphasis>Cryptosporidium meleagridis</emphasis></citetitle> among high school students of dormitory in Ehime, Japan. <citetitle><emphasis>Annu Rep Ehime Prefect Inst Public Health Environ Sci</emphasis></citetitle> <emphasis role="strong">9:</emphasis>21–25.</para>
          </listitem>
          <listitem id="ch0169s000000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Bujila I, Troell K, Fischerström K, Nordahl M, Killander G, Hansen A, Söderlund R, Lebbad M, Beser J.</emphasis> 2021. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> chipmunk genotype I—an emerging cause of human cryptosporidiosis in Sweden. <citetitle><emphasis>Infect Genet Evol</emphasis></citetitle> <emphasis role="strong">92:</emphasis>104895.</para>
          </listitem>
          <listitem id="ch0169s000000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Ryan U, Hijjawi N, Xiao L.</emphasis> 2018. Foodborne cryptosporidiosis. <citetitle><emphasis>Int J Parasitol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1–12.</para>
          </listitem>
          <listitem id="ch0169s000000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Budu-Amoako E, Greenwood SJ, Dixon BR, Barkema HW, McClure JT.</emphasis> 2011. Foodborne illness associated with <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> and <citetitle><emphasis>Giardia</emphasis></citetitle> from livestock. <citetitle><emphasis>J Food Prot</emphasis></citetitle> <emphasis role="strong">74:</emphasis>1944–1955.</para>
          </listitem>
          <listitem id="ch0169s000000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Dixon B, Parrington L, Cook A, Pollari F, Farber J.</emphasis> 2013. Detection of <citetitle><emphasis>Cyclospora</emphasis></citetitle>, <citetitle><emphasis>Cryptosporidium</emphasis></citetitle>, and <citetitle><emphasis>Giardia</emphasis></citetitle> in ready-to-eat packaged leafy greens in Ontario, Canada. <citetitle><emphasis>J Food Prot</emphasis></citetitle> <emphasis role="strong">76:</emphasis>307–313.</para>
          </listitem>
          <listitem id="ch0169s000000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Hong S, Kim K, Yoon S, Park WY, Sim S, Yu JR.</emphasis> 2014. Detection of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> in environmental soil and vegetables. <citetitle><emphasis>J Korean Med Sci</emphasis></citetitle> <emphasis role="strong">29:</emphasis>1367–1371.</para>
          </listitem>
          <listitem id="ch0169s000000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Berrouch S, Escotte-Binet S, Amraouza Y, Flori P, Aubert D, Villena I, Hafid J.</emphasis> 2020. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp., <citetitle><emphasis>Giardia duodenalis</emphasis></citetitle> and <citetitle><emphasis>Toxoplasma gondii</emphasis></citetitle> detection in fresh vegetables consumed in Marrakech, Morocco. <citetitle><emphasis>Afr Health Sci</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1669–1678.</para>
          </listitem>
          <listitem id="ch0169s000000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Sakkas H, Economou V, Bozidis P, Gousia P, Papadopoulou C, Karanis P.</emphasis> 2020. Detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> and <citetitle><emphasis>Giardia</emphasis></citetitle> in foods of plant origin in North-Western Greece. <citetitle><emphasis>J Water Health</emphasis></citetitle> <emphasis role="strong">18:</emphasis>574–578.</para>
          </listitem>
          <listitem id="ch0169s000000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Li J, Wang Z, Karim MR, Zhang L.</emphasis> 2020. Detection of human intestinal protozoan parasites in vegetables and fruits: a review. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">13:</emphasis>380.</para>
          </listitem>
          <listitem id="ch0169s000000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Marquis ND, Bishop TJ, Record NR, Countway PD, Fernández Robledo JA.</emphasis> 2019. Molecular epizootiology of <citetitle><emphasis>Toxoplasma gondii</emphasis></citetitle> and <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> in the eastern oyster (<citetitle><emphasis>Crassostrea virginica</emphasis></citetitle>) from Maine (USA). <citetitle><emphasis>Pathogens</emphasis></citetitle> <emphasis role="strong">8:</emphasis>125.</para>
          </listitem>
          <listitem id="ch0169s000000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Gherasim A, Lebbad M, Insulander M, Decraene V, Kling A, Hjertqvist M, Wallensten A.</emphasis> 2012. Two geographically separated food-borne outbreaks in Sweden linked by an unusual <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> subtype, October 2010. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">17:</emphasis>20318.</para>
          </listitem>
          <listitem id="ch0169s000000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">McKerr C, Adak GK, Nichols G, Gorton R, Chalmers RM, Kafatos G, Cosford P, Charlett A, Reacher M, Pollock KG, Alexander CL, Morton S.</emphasis> 2015. An outbreak of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> across England &amp; Scotland associated with consumption of fresh pre-cut salad leaves, May 2012. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e0125955.</para>
          </listitem>
          <listitem id="ch0169s000000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Rosenthal M, Pedersen R, Leibsle S, Hill V, Carter K, Roellig DM, Centers for Disease Control and Prevention (CDC).</emphasis> 2015. Notes from the field: cryptosporidiosis associated with consumption of unpasteurized goat milk—Idaho, 2014. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">64:</emphasis>194–195.</para>
          </listitem>
          <listitem id="ch0169s000000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Robinson TJ, Scheftel JM, Smith KE.</emphasis> 2014. Raw milk consumption among patients with non-outbreak-related enteric infections, Minnesota, USA, 2001–2010. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>38–44.</para>
          </listitem>
          <listitem id="ch0169s000000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Åberg R, Sjöman M, Hemminki K, Pirnes A, Räsänen S, Kalanti A, Pohjanvirta T, Caccio SM, Pihlajasaari A, Toikkanen S, Huusko S, Rimhanen-Finne R.</emphasis> 2015. <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> caused a large outbreak linked to Frisee salad in Finland, 2012. <citetitle><emphasis>Zoonoses Public Health</emphasis></citetitle> <emphasis role="strong">62:</emphasis>618–624.</para>
          </listitem>
          <listitem id="ch0169s000000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Centers for Disease Control and Prevention (CDC).</emphasis> 2011. Cryptosporidiosis outbreak at a summer camp—North Carolina, 2009. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">60:</emphasis>918–922.</para>
          </listitem>
          <listitem id="ch0169s000000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Ursini T, Moro L, Requena-Méndez A, Bertoli G, Buonfrate D.</emphasis> 2020. A review of outbreaks of cryptosporidiosis due to unpasteurized milk. <citetitle><emphasis>Infection</emphasis></citetitle> <emphasis role="strong">48:</emphasis>659–663.</para>
          </listitem>
          <listitem id="ch0169s000000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Robertson LJ, Temesgen TT, Tysnes KR, Eikås JE.</emphasis> 2019. An apple a day: an outbreak of cryptosporidiosis in Norway associated with self-pressed apple juice. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">147:</emphasis>e139.</para>
          </listitem>
          <listitem id="ch0169s000000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Patanasatienkul T, Greenwood SJ, McClure JT, Davidson J, Gardner I, Sanchez J.</emphasis> 2020. Bayesian risk assessment model of human cryptosporidiosis cases following consumption of raw Eastern oysters (<citetitle><emphasis>Crassostrea virginica</emphasis></citetitle>) contaminated with <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> oocysts in the Hillsborough River system in Prince Edward Island, Canada. <citetitle><emphasis>Food Waterborne Parasitol</emphasis></citetitle> <emphasis role="strong">19:</emphasis>e00079.</para>
          </listitem>
          <listitem id="ch0169s000000li0095" role="bibliographyEntry">
            <anchor id="ch0169s000000a0078"/>
            <para>95.<emphasis role="strong">Pereira MD, Atwill ER, Barbosa AP, Silva SA, García-Zapata MT.</emphasis> 2002. Intra-familial and extra-familial risk factors associated with <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> infection among children hospitalized for diarrhea in Goiânia, Goiás, Brazil. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">66:</emphasis>787–793.</para>
          </listitem>
          <listitem id="ch0169s000000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Grace D, Monda J, Karanja N, Randolph TF, Kang’ethe EK.</emphasis> 2012. Participatory probabilistic assessment of the risk to human health associated with cryptosporidiosis from urban dairying in Dagoretti, Nairobi, <citetitle><emphasis>Kenya. Trop Anim Health Prod</emphasis></citetitle> <emphasis role="strong">44</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S33–S40.</para>
          </listitem>
          <listitem id="ch0169s000000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Robertson B, Sinclair MI, Forbes AB, Veitch M, Kirk M, Cunliffe D, Willis J, Fairley CK.</emphasis> 2002. Case-control studies of sporadic cryptosporidiosis in Melbourne and Adelaide, Australia. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">128:</emphasis>419–431.</para>
          </listitem>
          <listitem id="ch0169s000000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Valderrama AL, Hlavsa MC, Cronquist A, Cosgrove S, Johnston SP, Roberts JM, Stock ML, Xiao L, Xavier K, Beach MJ.</emphasis> 2009. Multiple risk factors associated with a large statewide increase in cryptosporidiosis. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">137:</emphasis>1781–1788.</para>
          </listitem>
          <listitem id="ch0169s000000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Certad G, Viscogliosi E, Chabé M, Cacciò SM.</emphasis> 2017. Pathogenic mechanisms of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> and <citetitle><emphasis>Giardia. Trends Parasitol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>561–576.</para>
          </listitem>
          <listitem id="ch0169s000000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Chalmers RM, Davies AP.</emphasis> 2010. Minireview: clinical cryptosporidiosis. <citetitle><emphasis>Exp Parasitol</emphasis></citetitle> <emphasis role="strong">124:</emphasis>138–146.</para>
          </listitem>
          <listitem id="ch0169s000000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Steiner KL, Ahmed S, Gilchrist CA, Burkey C, Cook H, Ma JZ, Korpe PS, Ahmed E, Alam M, Kabir M, Tofail F, Ahmed T, Haque R, Petri WA Jr, Faruque ASG.</emphasis> 2018. Species of cryptosporidia causing subclinical infection associated with growth faltering in rural and urban Bangladesh: a birth cohort study. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1347–1355.</para>
          </listitem>
          <listitem id="ch0169s000000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Korpe PS, Valencia C, Haque R, Mahfuz M, McGrath M, Houpt E, Kosek M, McCormick BJJ, Penataro Yori P, Babji S, Kang G, Lang D, Gottlieb M, Samie A, Bessong P, Faruque ASG, Mduma E, Nshama R, Havt A, Lima IFN, Lima AAM, Bodhidatta L, Shreshtha A, Petri WA Jr, Ahmed T, Duggal P.</emphasis> 2018. Epidemiology and risk factors for cryptosporidiosis in children from 8 low-income sites: results from the MAL-ED Study. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1660–1669.</para>
          </listitem>
          <listitem id="ch0169s000000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Cama VA, Bern C, Roberts J, Cabrera L, Sterling CR, Ortega Y, Gilman RH, Xiao L.</emphasis> 2008. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species and subtypes and clinical manifestations in children, Peru. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>1567–1574.</para>
          </listitem>
          <listitem id="ch0169s000000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Kabir M, Alam M, Nayak U, Arju T, Hossain B, Tarannum R, Khatun A, White JA, Ma JZ, Haque R, Petri WA Jr, Gilchrist CA.</emphasis> 2021. Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition. <citetitle><emphasis>PLoS Pathog</emphasis></citetitle> <emphasis role="strong">17:</emphasis>e1009445.</para>
          </listitem>
          <listitem id="ch0169s000000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Korpe PS, Gilchrist C, Burkey C, Taniuchi M, Ahmed E, Madan V, Castillo R, Ahmed S, Arju T, Alam M, Kabir M, Ahmed T, Petri WA, Haque R, Faruque ASG, Duggal P.</emphasis> 2019. Case-control study of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> transmission in Bangladeshi households. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">68:</emphasis>1073–1079.</para>
          </listitem>
          <listitem id="ch0169s000000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Sarkar R, Tate JE, Ajjampur SS, Kattula D, John J, Ward HD, Kang G.</emphasis> 2014. Burden of diarrhea, hospitalization and mortality due to cryptosporidial infections in Indian children. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e3042.</para>
          </listitem>
          <listitem id="ch0169s000000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Iglói Z, Mughini-Gras L, Nic Lochlainn L, Barrasa A, Sane J, Mooij S, Schimmer B, Roelfsema J, van Pelt W, Kortbeek T.</emphasis> 2018. Long-term sequelae of sporadic cryptosporidiosis: a follow-up study. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">37:</emphasis>1377–1384.</para>
          </listitem>
          <listitem id="ch0169s000000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Carter BL, Stiff RE, Elwin K, Hutchings HA, Mason BW, Davies AP, Chalmers RM.</emphasis> 2019. Health sequelae of human cryptosporidiosis—a 12-month prospective follow-up study. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">38:</emphasis>1709–1717.</para>
          </listitem>
          <listitem id="ch0169s000000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Goh S, Reacher M, Casemore DP, Verlander NQ, Chalmers R, Knowles M, Williams J, Osborn K, Richards S.</emphasis> 2004. Sporadic cryptosporidiosis, North Cumbria, England, 1996–2000. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1007–1015.</para>
          </listitem>
          <listitem id="ch0169s000000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Dietz V, Vugia D, Nelson R, Wicklund J, Nadle J, McCombs KG, Reddy S.</emphasis> 2000. Active, multisite, laboratory-based surveillance for <citetitle><emphasis>Cryptosporidium parvum. Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">62:</emphasis>368–372.</para>
          </listitem>
          <listitem id="ch0169s000000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Ng-Hublin JSY, Combs B, Reid S, Ryan U.</emphasis> 2018. Comparison of three cryptosporidiosis outbreaks in Western Australia: 2003, 2007 and 2011. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">146:</emphasis>1413–1424.</para>
          </listitem>
          <listitem id="ch0169s000000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Hunter PR, Hughes S, Woodhouse S, Raj N, Syed Q, Chalmers RM, Verlander NQ, Goodacre J.</emphasis> 2004. Health sequelae of human cryptosporidiosis in immunocompetent patients. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">39:</emphasis>504–510.</para>
          </listitem>
          <listitem id="ch0169s000000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Carter BL, Chalmers RM, Davies AP.</emphasis> 2020. Health sequelae of human cryptosporidiosis in industrialised countries: a systematic review. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">13:</emphasis>443.</para>
          </listitem>
          <listitem id="ch0169s000000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Hunter PR, Nichols G.</emphasis> 2002. Epidemiology and clinical features of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection in immunocompromised patients. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">15:</emphasis>145–154.</para>
          </listitem>
          <listitem id="ch0169s000000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">De Angelis C, Mangone M, Bianchi M, Saracco G, Repici A, Rizzetto M, Pellicano R.</emphasis> 2009. An update on AIDS-related cholangiopathy. <citetitle><emphasis>Minerva Gastroenterol Dietol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>79–82.</para>
          </listitem>
          <listitem id="ch0169s000000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Rahman M, Chapel H, Chapman RW, Collier JD.</emphasis> 2012. Cholangiocarcinoma complicating secondary sclerosing cholangitis from cryptosporidiosis in an adult patient with CD40 ligand deficiency: case report and review of the literature. <citetitle><emphasis>Int Arch Allergy Immunol</emphasis></citetitle> <emphasis role="strong">159:</emphasis>204–208.</para>
          </listitem>
          <listitem id="ch0169s000000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Domenech C, Rabodonirina M, Bleyzac N, Pagès MP, Bertrand Y.</emphasis> 2011. Cryptosporidiosis in children with acute lymphoblastic leukemia on maintenance chemotherapy. <citetitle><emphasis>J Pediatr Hematol Oncol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>570–572.</para>
          </listitem>
          <listitem id="ch0169s000000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Dupuy F, Valot S, Dalle F, Sterin A, L’Ollivier C.</emphasis> 2021. Disseminated <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection in an infant with CD40L deficiency. <citetitle><emphasis>IDCases</emphasis></citetitle> <emphasis role="strong">24:</emphasis>e01115.</para>
          </listitem>
          <listitem id="ch0169s000000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Fischer RT, Day JC, Wasserkrug H, Faseler M, Kats A, Daniel JF, Slowik V, Andrews W, Hendrickson RJ.</emphasis> 2020. Complications of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection after pediatric liver transplantation: diarrhea, rejection, and biliary disease. <citetitle><emphasis>Pediatr Transplant</emphasis></citetitle> <emphasis role="strong">24:</emphasis>e13807.</para>
          </listitem>
          <listitem id="ch0169s000000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Tali A, Addebbous A, Asmama S, Chabaa L, Zougaghi L.</emphasis> 2011. Respiratory cryptosporidiosis in two patients with HIV infection in a tertiary care hospital in Morocco. <citetitle><emphasis>Ann Biol Clin (Paris)</emphasis></citetitle> <emphasis role="strong">69:</emphasis>605–608.</para>
          </listitem>
          <listitem id="ch0169s000000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Iroh Tam PY, Chisala M, Nyangulu W, Thole H, Nyirenda J.</emphasis> 2021. Respiratory cryptosporidiosis in Malawian children with diarrheal disease. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>e0009643.</para>
          </listitem>
          <listitem id="ch0169s000000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Bern C, Kawai V, Vargas D, Rabke-Verani J, Williamson J, Chavez-Valdez R, Xiao L, Sulaiman I, Vivar A, Ticona E, Navincopa M, Cama V, Moura H, Secor WE, Visvesvara G, Gilman RH.</emphasis> 2005. The epidemiology of intestinal microsporidiosis in patients with HIV/AIDS in Lima, Peru. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">191:</emphasis>1658–1664.</para>
          </listitem>
          <listitem id="ch0169s000000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Cama VA, Ross JM, Crawford S, Kawai V, Chavez-Valdez R, Vargas D, Vivar A, Ticona E, Navincopa M, Williamson J, Ortega Y, Gilman RH, Bern C, Xiao L.</emphasis> 2007. Differences in clinical manifestations among <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species and subtypes in HIV-infected persons. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">196:</emphasis>684–691.</para>
          </listitem>
          <listitem id="ch0169s000000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Chalmers RM, Katzer F.</emphasis> 2013. Looking for <citetitle><emphasis>Cryptosporidium</emphasis></citetitle>: the application of advances in detection and diagnosis. <citetitle><emphasis>Trends Parasitol</emphasis></citetitle> <emphasis role="strong">29:</emphasis>237–251.</para>
          </listitem>
          <listitem id="ch0169s000000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Abdelsalam IM, Sarhan RM, Hanafy MA.</emphasis> 2017. The impact of different copro-preservation conditions on molecular detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species. <citetitle><emphasis>Iran J Parasitol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>274–283.</para>
          </listitem>
          <listitem id="ch0169s000000li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Nétor Velásquez J, Marta E, Alicia di Risio C, Etchart C, Gancedo E, Victor Chertcoff A, Bruno Malandrini J, Germán Astudillo O, Carnevale S.</emphasis> 2012. Molecular identification of protozoa causing AIDS-associated cholangiopathy in Buenos Aires, Argentina. <citetitle><emphasis>Acta Gastroenterol Latinoam</emphasis></citetitle> <emphasis role="strong">42:</emphasis>301–308.</para>
          </listitem>
          <listitem id="ch0169s000000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">O’Leary JK, Sleator RD, Lucey B.</emphasis> 2021. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. diagnosis and research in the 21st century. <citetitle><emphasis>Food Waterborne Parasitol</emphasis></citetitle> <emphasis role="strong">24:</emphasis>e00131.</para>
          </listitem>
          <listitem id="ch0169s000000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Robinson G, Chalmers RM.</emphasis> 2020. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> diagnostic assays: microscopy. <citetitle><emphasis>Methods Mol Biol</emphasis></citetitle> <emphasis role="strong">2052:</emphasis>1–10.</para>
          </listitem>
          <listitem id="ch0169s000000li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Chalmers RM, Atchison C, Barlow K, Young Y, Roche A, Manuel R.</emphasis> 2015. An audit of the laboratory diagnosis of cryptosporidiosis in England and Wales. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">64:</emphasis>688–693.</para>
          </listitem>
          <listitem id="ch0169s000000li0130" role="bibliographyEntry">
            <anchor id="ch0169s000000a0079"/>
            <para>130.<emphasis role="strong">Johansen OH, Abdissa A, Zangenberg M, Mekonnen Z, Eshetu B, Bjørang O, Alemu Y, Sharew B, Langeland N, Robertson LJ, Hanevik K.</emphasis> 2021. Performance and operational feasibility of two diagnostic tests for cryptosporidiosis in children (CRYPTO-POC): a clinical, prospective, diagnostic accuracy study. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>722–730.</para>
          </listitem>
          <listitem id="ch0169s000000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Iwashita H, Takemura T, Tokizawa A, Sugamoto T, Thiem VD, Nguyen TH, Pham TD, Pham AHQ, Doan HT, Tran NL, Yamashiro T.</emphasis> 2021. Molecular epidemiology of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. in an agricultural area of northern Vietnam: a community survey. <citetitle><emphasis>Parasitol Int</emphasis></citetitle> <emphasis role="strong">83:</emphasis>102341.</para>
          </listitem>
          <listitem id="ch0169s000000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Wang G, Wang G, Li X, Zhang X, Karanis G, Jian Y, Ma L, Karanis P.</emphasis> 2018. Prevalence and molecular characterization of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. and <citetitle><emphasis>Giardia duodenalis</emphasis></citetitle> in 1-2-month-old highland yaks in Qinghai Province, China. <citetitle><emphasis>Parasitol Res</emphasis></citetitle> <emphasis role="strong">117:</emphasis>1793–1800.</para>
          </listitem>
          <listitem id="ch0169s000000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Tangtrongsup S, Scorza AV, Reif JS, Ballweber LR, Lappin MR, Salman MD.</emphasis> 2020. Seasonal distributions and other risk factors for <citetitle><emphasis>Giardia duodenalis</emphasis></citetitle> and <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. infections in dogs and cats in Chiang Mai, Thailand. <citetitle><emphasis>Prev Vet Med</emphasis></citetitle> <emphasis role="strong">174:</emphasis>104820.</para>
          </listitem>
          <listitem id="ch0169s000000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Chalmers RM, Campbell BM, Crouch N, Charlett A, Davies AP.</emphasis> 2011. Comparison of diagnostic sensitivity and specificity of seven <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> assays used in the UK. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>1598–1604.</para>
          </listitem>
          <listitem id="ch0169s000000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Webster KA, Smith HV, Giles M, Dawson L, Robertson LJ.</emphasis> 1996. Detection of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> oocysts in faeces: comparison of conventional coproscopical methods and the polymerase chain reaction. <citetitle><emphasis>Vet Parasitol</emphasis></citetitle> <emphasis role="strong">61:</emphasis>5–13.</para>
          </listitem>
          <listitem id="ch0169s000000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Weber R, Bryan RT, Bishop HS, Wahlquist SP, Sullivan JJ, Juranek DD.</emphasis> 1991. Threshold of detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> oocysts in human stool specimens: evidence for low sensitivity of current diagnostic methods. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">29:</emphasis>1323–1327.</para>
          </listitem>
          <listitem id="ch0169s000000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Rimhanen-Finne R, Enemark HL, Kolehmainen J, Toropainen P, Hänninen ML.</emphasis> 2007. Evaluation of immunofluorescence microscopy and enzyme-linked immunosorbent assay in detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> and <citetitle><emphasis>Giardia</emphasis></citetitle> infections in asymptomatic dogs. <citetitle><emphasis>Vet Parasitol</emphasis></citetitle> <emphasis role="strong">145:</emphasis>345–348.</para>
          </listitem>
          <listitem id="ch0169s000000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Garcia LS, Brewer TC, Bruckner DA.</emphasis> 1987. Fluorescence detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> oocysts in human fecal specimens by using monoclonal antibodies. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">25:</emphasis>119–121.</para>
          </listitem>
          <listitem id="ch0169s000000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Johnston SP, Ballard MM, Beach MJ, Causer L, Wilkins PP.</emphasis> 2003. Evaluation of three commercial assays for detection of <citetitle><emphasis>Giardia</emphasis></citetitle> and <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> organisms in fecal specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>623–626.</para>
          </listitem>
          <listitem id="ch0169s000000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Kabir M, Ahmed E, Hossain B, Alam M, Ahmed S, Taniuchi M, Gilchrist CA, Houpt ER, Faruque ASG, Petri WA Jr, Haque R.</emphasis> 2018. <citetitle><emphasis>Giardia</emphasis></citetitle>/<citetitle><emphasis>Cryptosporidium</emphasis></citetitle> QUIK CHEK(R) Assay is more specific than qPCR for rapid point-of-care diagnosis of cryptosporidiosis in infants in Bangladesh. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1897–1903.</para>
          </listitem>
          <listitem id="ch0169s000000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Bialek R, Binder N, Dietz K, Joachim A, Knobloch J, Zelck UE.</emphasis> 2002. Comparison of fluorescence, antigen and PCR assays to detect <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> in fecal specimens. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">43:</emphasis>283–288.</para>
          </listitem>
          <listitem id="ch0169s000000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Razakandrainibe R, Mérat C, Kapel N, Sautour M, Guyot K, Gargala G, Ballet JJ, Le Pape P, Dalle F, Favennec L, French Cryptosporidiosis Network.</emphasis> 2021. Multicenter evaluation of an ELISA for the detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. antigen in clinical human stool samples. <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">9:</emphasis>209.</para>
          </listitem>
          <listitem id="ch0169s000000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Danišová O, Halánová M, Valenčáková A, Luptáková L.</emphasis> 2018. Sensitivity, specificity and comparison of three commercially available immunological tests in the diagnosis of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species in animals. <citetitle><emphasis>Braz J Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>177–183.</para>
          </listitem>
          <listitem id="ch0169s000000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">El-Moamly AA, El-Sweify MA.</emphasis> 2012. ImmunoCard STAT! cartridge antigen detection assay compared to microplate enzyme immunoassay and modified Kinyoun’s acid-fast staining technique for detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> in fecal specimens. <citetitle><emphasis>Parasitol Res</emphasis></citetitle> <emphasis role="strong">110:</emphasis>1037–1041.</para>
          </listitem>
          <listitem id="ch0169s000000li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Karadam SY, Ertu</emphasis>ğ <emphasis role="strong">S, Ertabaklar H.</emphasis> 2016. Comparative evaluation of three methods (microscopic examination, direct fluorescent antibody assay, and immunochromatographic method) for the diagnosis of <citetitle><emphasis>Giardia intestinalis</emphasis></citetitle> from stool specimens. <citetitle><emphasis>Turkiye Parazitol Derg</emphasis></citetitle> <emphasis role="strong">40:</emphasis>22–25.</para>
          </listitem>
          <listitem id="ch0169s000000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Banisch DM, El-Badry A, Klinnert JV, Ignatius R, El-Dib N.</emphasis> 2015. Simultaneous detection of <citetitle><emphasis>Entamoeba histolytica/dispar</emphasis></citetitle>, <citetitle><emphasis>Giardia duodenalis</emphasis></citetitle> and cryptosporidia by immunochromatographic assay in stool samples from patients living in the Greater Cairo Region, Egypt. <citetitle><emphasis>World J Microbiol Biotechnol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>1251–1258.</para>
          </listitem>
          <listitem id="ch0169s000000li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Fleece ME, Heptinstall J, Khan SS, Kabir M, Herbein J, Haque R, Petri WA Jr.</emphasis> 2016. Evaluation of a rapid lateral flow point-of-care test for detection of <citetitle><emphasis>Cryptosporidium. Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">95:</emphasis>840–841.</para>
          </listitem>
          <listitem id="ch0169s000000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Goudal A, Laude A, Valot S, Desoubeaux G, Argy N, Nourrisson C, Pomares C, Machouart M, Le Govic Y, Dalle F, Botterel F, Bourgeois N, Cateau E, Leterrier M, Lavergne RA, Beser J, Le Pape P, Morio F.</emphasis> 2018. Rapid diagnostic tests relying on antigen detection from stool as an efficient point of care testing strategy for giardiasis and cryptosporidiosis? Evaluation of a new immunochromatographic duplex assay. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">93:</emphasis>33–36.</para>
          </listitem>
          <listitem id="ch0169s000000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Weitzel T, Dittrich S, Möhl I, Adusu E, Jelinek T.</emphasis> 2006. Evaluation of seven commercial antigen detection tests for <citetitle><emphasis>Giardia</emphasis></citetitle> and <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> in stool samples. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">12:</emphasis>656–659.</para>
          </listitem>
          <listitem id="ch0169s000000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Goñi P, Martín B, Villacampa M, García A, Seral C, Castillo FJ, Clavel A.</emphasis> 2012. Evaluation of an immunochromatographic dip strip test for simultaneous detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp., <citetitle><emphasis>Giardia duodenalis</emphasis></citetitle>, and <citetitle><emphasis>Entamoeba histolytica</emphasis></citetitle> antigens in human faecal samples. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">31:</emphasis>2077–2082.</para>
          </listitem>
          <listitem id="ch0169s000000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Agnamey P, Sarfati C, Pinel C, Rabodoniriina M, Kapel N, Dutoit E, Garnaud C, Diouf M, Garin JF, Totet A, Derouin F, ANOFEL Cryptosporidium National Network.</emphasis> 2011. Evaluation of four commercial rapid immunochromatographic assays for detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> antigens in stool samples: a blind multicenter trial. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1605–1607.</para>
          </listitem>
          <listitem id="ch0169s000000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Vanathy K, Parija SC, Mandal J, Hamide A, Krishnamurthy S.</emphasis> 2017. Detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> in stool samples of immunocompromised patients. <citetitle><emphasis>Trop Parasitol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>41–46.</para>
          </listitem>
          <listitem id="ch0169s000000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Robinson TJ, Cebelinski EA, Taylor C, Smith KE.</emphasis> 2010. Evaluation of the positive predictive value of rapid assays used by clinical laboratories in Minnesota for the diagnosis of cryptosporidiosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>e53–e55.</para>
          </listitem>
          <listitem id="ch0169s000000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Roellig DM, Yoder JS, Madison-Antenucci S, Robinson TJ, Van TT, Collier SA, Boxrud D, Monson T, Bates LA, Blackstock AJ, Shea S, Larson K, Xiao L, Beach M.</emphasis> 2017. Community laboratory testing for <citetitle><emphasis>Cryptosporidium</emphasis></citetitle>: multicenter study retesting public health surveillance stool samples positive for <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> by rapid cartridge assay with direct fluorescent antibody testing. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0169915.</para>
          </listitem>
          <listitem id="ch0169s000000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Robinson G, Elwin K, Chalmers RM.</emphasis> 2020. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> diagnostic assays: molecular detection. <citetitle><emphasis>Methods Mol Biol</emphasis></citetitle> <emphasis role="strong">2052:</emphasis>11–22.</para>
          </listitem>
          <listitem id="ch0169s000000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Vejdani M, Mansour R, Hamzavi Y, Vejdani S, Nazeri N, Michaeli A.</emphasis> 2014. Immunofluorescence assay and PCR analysis of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> oocysts and species from human faecal specimens. <citetitle><emphasis>Jundishapur J Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e10284.</para>
          </listitem>
          <listitem id="ch0169s000000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Alsuwaidi AR, Al Dhaheri K, Al Hamad S, George J, Ibrahim J, Ghatasheh G, Issa M, Al-Hammadi S, Narchi H.</emphasis> 2021. Etiology of diarrhea by multiplex polymerase chain reaction among young children in the United Arab Emirates: a case-control study. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>7.</para>
          </listitem>
          <listitem id="ch0169s000000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Hannet I, Engsbro AL, Pareja J, Schneider UV, Lisby JG, Pružinec-Popovi</emphasis>ć <emphasis role="strong">B, Hoerauf A, Par</emphasis>č<emphasis role="strong">ina M.</emphasis> 2019. Multicenter evaluation of the new QIAstat Gastrointestinal Panel for the rapid syndromic testing of acute gastroenteritis. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">38:</emphasis>2103–2112.</para>
          </listitem>
          <listitem id="ch0169s000000li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Mergen K, Espina N, Teal A, Madison-Antenucci S.</emphasis> 2020. Detecting <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> in stool samples submitted to a reference laboratory. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">103:</emphasis>421–427.</para>
          </listitem>
          <listitem id="ch0169s000000li0160" role="bibliographyEntry">
            <anchor id="ch0169s000000a0080"/>
            <para>160.<emphasis role="strong">Zhan Z, Guo J, Xiao Y, He Z, Xia X, Huang Z, Guan H, Ling X, Li J, Diao B, Zhao H, Kan B, Zhang J.</emphasis> 2020. Comparison of BioFire FilmArray gastrointestinal panel versus Luminex xTAG Gastrointestinal Pathogen Panel (xTAG GPP) for diarrheal pathogen detection in China. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">99:</emphasis>414–420.</para>
          </listitem>
          <listitem id="ch0169s000000li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Wang C, Zhou X, Zhu M, Yin H, Tang J, Huang Y, Zheng B, Jin Y, Liu Z.</emphasis> 2020. The application research of xTAG GPP multiplex PCR in the diagnosis of persistent and chronic diarrhea in children. <citetitle><emphasis>BMC Pediatr</emphasis></citetitle> <emphasis role="strong">20:</emphasis>309.</para>
          </listitem>
          <listitem id="ch0169s000000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Ryan U, Paparini A, Oskam C.</emphasis> 2017. New technologies for detection of enteric parasites. <citetitle><emphasis>Trends Parasitol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>532–546.</para>
          </listitem>
          <listitem id="ch0169s000000li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Duong VT, Phat VV, Tuyen HT, Dung TT, Trung PD, Minh PV, Tu TP, Campbell JI, Le Phuc H, Ha TT, Ngoc NM, Huong NT, Tam PT, Huong DT, Xang NV, Dong N, Phuong T, Hung NV, Phu BD, Phuc TM, Thwaites GE, Vi LL, Rabaa MA, Thompson CN, Baker S.</emphasis> 2016. Evaluation of Luminex xTAG gastrointestinal pathogen panel assay for detection of multiple diarrheal pathogens in fecal samples in Vietnam. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1094–1100.</para>
          </listitem>
          <listitem id="ch0169s000000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Calderaro A, Martinelli M, Buttrini M, Montecchini S, Covan S, Rossi S, Ferraglia F, Montagna P, Pinardi F, Larini S, Arcangeletti MC, Medici MC, Chezzi C, De Conto F.</emphasis> 2018. Contribution of the FilmArray<superscript>®</superscript> Gastrointestinal Panel in the laboratory diagnosis of gastroenteritis in a cohort of children: a two-year prospective study. <citetitle><emphasis>Int J Med Microbiol</emphasis></citetitle> <emphasis role="strong">308:</emphasis>514–521.</para>
          </listitem>
          <listitem id="ch0169s000000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Batra R, Judd E, Eling J, Newsholme W, Goldenberg SD.</emphasis> 2016. Molecular detection of common intestinal parasites: a performance evaluation of the BD Max™ Enteric Parasite Panel. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">35:</emphasis>1753–1757.</para>
          </listitem>
          <listitem id="ch0169s000000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Madison-Antenucci S, Relich RF, Doyle L, Espina N, Fuller D, Karchmer T, Lainesse A, Mortensen JE, Pancholi P, Veros W, Harrington SM.</emphasis> 2016. Multicenter evaluation of BD Max Enteric Parasite Real-Time PCR assay for detection of <citetitle><emphasis>Giardia duodenalis</emphasis></citetitle>, <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle>, <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle>, and <citetitle><emphasis>Entamoeba histolytica. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2681–2688.</para>
          </listitem>
          <listitem id="ch0169s000000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Mölling P, Nilsson P, Ennefors T, Ögren J, Florén K, Thulin Hedberg S, Sundqvist M.</emphasis> 2016. Evaluation of the BD Max Enteric Parasite Panel for clinical diagnostics. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>443–444.</para>
          </listitem>
          <listitem id="ch0169s000000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Laude A, Valot S, Desoubeaux G, Argy N, Nourrisson C, Pomares C, Machouart M, Le Govic Y, Dalle F, Botterel F, Bourgeois N, Cateau E, Leterrier M, Le Pape P, Morio F.</emphasis> 2016. Is real-time PCR-based diagnosis similar in performance to routine parasitological examination for the identification of <citetitle><emphasis>Giardia intestinalis</emphasis></citetitle>, <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle>/<citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> and <citetitle><emphasis>Entamoeba histolytica</emphasis></citetitle> from stool samples? Evaluation of a new commercial multiplex PCR assay and literature review. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">22:</emphasis>190.e1–190.e8.</para>
          </listitem>
          <listitem id="ch0169s000000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Morio F, Poirier P, Le Govic Y, Laude A, Valot S, Desoubeaux G, Argy N, Nourrisson C, Pomares C, Machouart M, Dalle F, Botterel F, Bourgeois N, Cateau E, Leterrier M, Beser J, Lavergne RA, Le Pape P.</emphasis> 2019. Assessment of the first commercial multiplex PCR kit (ParaGENIE Crypto-Micro Real-Time PCR) for the detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp., <citetitle><emphasis>Enterocytozoon bieneusi</emphasis></citetitle>, and <citetitle><emphasis>Encephalitozoon intestinalis</emphasis></citetitle> from fecal samples. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">95:</emphasis>34–37.</para>
          </listitem>
          <listitem id="ch0169s000000li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Paulos S, Saugar JM, de Lucio A, Fuentes I, Mateo M, Carmena D.</emphasis> 2019. Comparative performance evaluation of four commercial multiplex real-time PCR assays for the detection of the diarrhoea-causing protozoa <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle>/<citetitle><emphasis>parvum</emphasis></citetitle>, <citetitle><emphasis>Giardia duodenalis</emphasis></citetitle> and <citetitle><emphasis>Entamoeba histolytica. PLoS One</emphasis></citetitle> <emphasis role="strong">14:</emphasis>e0215068.</para>
          </listitem>
          <listitem id="ch0169s000000li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Autier B, Belaz S, Razakandrainibe R, Gangneux JP, Robert-Gangneux F.</emphasis> 2018. Comparison of three commercial multiplex PCR assays for the diagnosis of intestinal protozoa. <citetitle><emphasis>Parasite</emphasis></citetitle> <emphasis role="strong">25:</emphasis>48.</para>
          </listitem>
          <listitem id="ch0169s000000li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, Operario DJ, Uddin J, Ahmed S, Alonso PL, Antonio M, Becker SM, Blackwelder WC, Breiman RF, Faruque AS, Fields B, Gratz J, Haque R, Hossain A, Hossain MJ, Jarju S, Qamar F, Iqbal NT, Kwambana B, Mandomando I, McMurry TL, Ochieng C, Ochieng JB, Ochieng M, Onyango C, Panchalingam S, Kalam A, Aziz F, Qureshi S, Ramamurthy T, Roberts JH, Saha D, Sow SO, Stroup SE, Sur D, Tamboura B, Taniuchi M, Tennant SM, Toema D, Wu Y, Zaidi A, Nataro JP, Kotloff KL, Levine MM, Houpt ER.</emphasis> 2016. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">388:</emphasis>1291–1301.</para>
          </listitem>
          <listitem id="ch0169s000000li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Rogawski ET, Liu J, Platts-Mills JA, Kabir F, Lertsethtakarn P, Siguas M, Khan SS, Praharaj I, Murei A, Nshama R, Mujaga B, Havt A, Maciel IA, Operario DJ, Taniuchi M, Gratz J, Stroup SE, Roberts JH, Kalam A, Aziz F, Qureshi S, Islam MO, Sakpaisal P, Silapong S, Yori PP, Rajendiran R, Benny B, McGrath M, Seidman JC, Lang D, Gottlieb M, Guerrant RL, Lima AAM, Leite JP, Samie A, Bessong PO, Page N, Bodhidatta L, Mason C, Shrestha S, Kiwelu I, Mduma ER, Iqbal NT, Bhutta ZA, Ahmed T, Haque R, Kang G, Kosek MN, Houpt ER, MAL-ED Network Investigators.</emphasis> 2018. Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study. <citetitle><emphasis>Lancet Glob Health</emphasis></citetitle> <emphasis role="strong">6:</emphasis>e1319–e1328.</para>
          </listitem>
          <listitem id="ch0169s000000li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Levine MM, Nasrin D, Acácio S, Bassat Q, Powell H, Tennant SM, Sow SO, Sur D, Zaidi AKM, Faruque ASG, Hossain MJ, Alonso PL, Breiman RF, O’Reilly CE, Mintz ED, Omore R, Ochieng JB, Oundo JO, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ahmed S, Qureshi S, Quadri F, Hossain A, Das SK, Antonio M, Saha D, Mandomando I, Blackwelder WC, Farag T, Wu Y, Houpt ER, Verweiij JJ, Sommerfelt H, Nataro JP, Robins-Browne RM, Kotloff KL.</emphasis> 2020. Diarrhoeal disease and subsequent risk of death in infants and children residing in low-income and middle-income countries: analysis of the GEMS case-control study and 12-month GEMS-1A follow-on study. <citetitle><emphasis>Lancet Glob Health</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e204–e214.</para>
          </listitem>
          <listitem id="ch0169s000000li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Xiao L.</emphasis> 2010. Molecular epidemiology of cryptosporidiosis: an update. <citetitle><emphasis>Exp Parasitol</emphasis></citetitle> <emphasis role="strong">124:</emphasis>80–89.</para>
          </listitem>
          <listitem id="ch0169s000000li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Ryan U, Fayer R, Xiao L.</emphasis> 2014. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species in humans and animals: current understanding and research needs. <citetitle><emphasis>Parasitology</emphasis></citetitle> <emphasis role="strong">141:</emphasis>1667–1685.</para>
          </listitem>
          <listitem id="ch0169s000000li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Xiao L, Escalante L, Yang C, Sulaiman I, Escalante AA, Montali RJ, Fayer R, Lal AA.</emphasis> 1999. Phylogenetic analysis of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> parasites based on the small-subunit rRNA gene locus. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">65:</emphasis>1578–1583.</para>
          </listitem>
          <listitem id="ch0169s000000li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Ryan U, Xiao L, Read C, Zhou L, Lal AA, Pavlasek I.</emphasis> 2003. Identification of novel <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> genotypes from the Czech Republic. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">69:</emphasis>4302–4307.</para>
          </listitem>
          <listitem id="ch0169s000000li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Hadfield SJ, Chalmers RM.</emphasis> 2012. Detection and characterization of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> cuniculus by real-time PCR. <citetitle><emphasis>Parasitol Res</emphasis></citetitle> <emphasis role="strong">111:</emphasis>1385–1390.</para>
          </listitem>
          <listitem id="ch0169s000000li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Hadfield SJ, Robinson G, Elwin K, Chalmers RM.</emphasis> 2011. Detection and differentiation of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. in human clinical samples by use of real-time PCR. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>918–924.</para>
          </listitem>
          <listitem id="ch0169s000000li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Staggs SE, Beckman EM, Keely SP, Mackwan R, Ware MW, Moyer AP, Ferretti JA, Sayed A, Xiao L, Villegas EN.</emphasis> 2013. The applicability of TaqMan-based quantitative real-time PCR assays for detecting and enumerating <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. oocysts in the environment. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e66562.</para>
          </listitem>
          <listitem id="ch0169s000000li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Mary C, Chapey E, Dutoit E, Guyot K, Hasseine L, Jeddi F, Menotti J, Paraud C, Pomares C, Rabodonirina M, Rieux A, Derouin F, ANOFEL Cryptosporidium National Network.</emphasis> 2013. Multicentric evaluation of a new real-time PCR assay for quantification of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. and identification of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> and <citetitle><emphasis>Cryptosporidium hominis. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2556–2563.</para>
          </listitem>
          <listitem id="ch0169s000000li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Burnet JB, Ogorzaly L, Tissier A, Penny C, Cauchie HM.</emphasis> 2013. Novel quantitative TaqMan real-time PCR assays for detection of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> at the genus level and genotyping of major human and cattle-infecting species. <citetitle><emphasis>J Appl Microbiol</emphasis></citetitle> <emphasis role="strong">114:</emphasis>1211–1222.</para>
          </listitem>
          <listitem id="ch0169s000000li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Yang R, Murphy C, Song Y, Ng-Hublin J, Estcourt A, Hijjawi N, Chalmers R, Hadfield S, Bath A, Gordon C, Ryan U.</emphasis> 2013. Specific and quantitative detection and identification of <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> and <citetitle><emphasis>C. parvum</emphasis></citetitle> in clinical and environmental samples. <citetitle><emphasis>Exp Parasitol</emphasis></citetitle> <emphasis role="strong">135:</emphasis>142–147.</para>
          </listitem>
          <listitem id="ch0169s000000li0185" role="bibliographyEntry">
            <anchor id="ch0169s000000a0081"/>
            <para>185.<emphasis role="strong">Bouzid M, Elwin K, Nader JL, Chalmers RM, Hunter PR, Tyler KM.</emphasis> 2016. Novel real-time PCR assays for the specific detection of human infective <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species. <citetitle><emphasis>Virulence</emphasis></citetitle> <emphasis role="strong">7:</emphasis>395–399.</para>
          </listitem>
          <listitem id="ch0169s000000li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Li N, Neumann NF, Ruecker N, Alderisio KA, Sturbaum GD, Villegas EN, Chalmers R, Monis P, Feng Y, Xiao L.</emphasis> 2015. Development and evaluation of three real-time PCR assays for genotyping and source tracking <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. in water. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">81:</emphasis>5845–5854.</para>
          </listitem>
          <listitem id="ch0169s000000li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Mahon M, Doyle S.</emphasis> 2017. Waterborne outbreak of cryptosporidiosis in the South East of Ireland: weighing up the evidence. <citetitle><emphasis>Ir J Med Sci</emphasis></citetitle> <emphasis role="strong">186:</emphasis>989–994.</para>
          </listitem>
          <listitem id="ch0169s000000li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Utsi L, Smith SJ, Chalmers RM, Padfield S.</emphasis> 2016. Cryptosporidiosis outbreak in visitors of a UK industry-compliant petting farm caused by a rare <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> subtype: a case-control study. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">144:</emphasis>1000–1009.</para>
          </listitem>
          <listitem id="ch0169s000000li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Roelfsema JH, Sprong H, Cacciò SM, Takumi K, Kroes M, van Pelt W, Kortbeek LM, van der Giessen JW.</emphasis> 2016. Molecular characterization of human <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> spp. isolates after an unusual increase in late summer 2012. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">9:</emphasis>138.</para>
          </listitem>
          <listitem id="ch0169s000000li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">Galuppi R, Piva S, Castagnetti C, Sarli G, Iacono E, Fioravanti ML, Caffara M.</emphasis> 2016. <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle>: from foal to veterinary students. <citetitle><emphasis>Vet Parasitol</emphasis></citetitle> <emphasis role="strong">219:</emphasis>53–56.</para>
          </listitem>
          <listitem id="ch0169s000000li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">DeSilva MB, Schafer S, Kendall Scott M, Robinson B, Hills A, Buser GL, Salis K, Gargano J, Yoder J, Hill V, Xiao L, Roellig D, Hedberg K.</emphasis> 2016. Communitywide cryptosporidiosis outbreak associated with a surface water-supplied municipal water system—Baker City, Oregon, 2013. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">144:</emphasis>274–284.</para>
          </listitem>
          <listitem id="ch0169s000000li0192" role="bibliographyEntry">
            <para>192.<emphasis role="strong">Cope JR, Prosser A, Nowicki S, Roberts MW, Roberts JM, Scheer D, Anderson C, Longsworth A, Parsons C, Goldschmidt D, Johnston S, Bishop H, Xiao L, Hill V, Beach M, Hlavsa MC.</emphasis> 2015. Preventing community-wide transmission of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle>: a proactive public health response to a swimming pool-associated outbreak—Auglaize County, Ohio, USA. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">143:</emphasis>3459–3467.</para>
          </listitem>
          <listitem id="ch0169s000000li0193" role="bibliographyEntry">
            <para>193.<emphasis role="strong">Polubotho P, Denvir L, Connelly L, Anderson E, Alexander CL.</emphasis> 2021. The first UK report of a rare <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> genetic variant isolated during a complex Scottish swimming pool outbreak. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">70</emphasis>(<link linkend="ch0169s000000li0003">3</link>). 10.1099/jmm.0.001289.</para>
          </listitem>
          <listitem id="ch0169s000000li0194" role="bibliographyEntry">
            <para>194.<emphasis role="strong">Braima K, Zahedi A, Egan S, Austen J, Xiao L, Feng Y, Witham B, Pingault N, Perera S, Oskam C, Reid S, Ryan U.</emphasis> 2021. Molecular analysis of cryptosporidiosis cases in Western Australia in 2019 and 2020 supports the occurrence of two swimming pool associated outbreaks and reveals the emergence of a rare <citetitle><emphasis>C. hominis</emphasis></citetitle> IbA12G3 subtype. <citetitle><emphasis>Infect Genet Evol</emphasis></citetitle> <emphasis role="strong">92:</emphasis>104859.</para>
          </listitem>
          <listitem id="ch0169s000000li0195" role="bibliographyEntry">
            <para>195.<emphasis role="strong">Hlavsa MC, Roberts VA, Kahler AM, Hilborn ED, Wade TJ, Backer LC, Yoder JS, Centers for Disease Control and Prevention (CDC).</emphasis> 2014. Recreational water-associated disease outbreaks—United States, 2009–2010. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">63:</emphasis>6–10.</para>
          </listitem>
          <listitem id="ch0169s000000li0196" role="bibliographyEntry">
            <para>196.<emphasis role="strong">Feng Y, Tiao N, Li N, Hlavsa M, Xiao L.</emphasis> 2014. Multilocus sequence typing of an emerging <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> subtype in the United States. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>524–530.</para>
          </listitem>
          <listitem id="ch0169s000000li0197" role="bibliographyEntry">
            <para>197.<emphasis role="strong">Li N, Xiao L, Cama VA, Ortega Y, Gilman RH, Guo M, Feng Y.</emphasis> 2013. Genetic recombination and <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> virulent subtype IbA10G2. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">19:</emphasis>1573–1582.</para>
          </listitem>
          <listitem id="ch0169s000000li0198" role="bibliographyEntry">
            <para>198.<emphasis role="strong">Chalmers RM, Robinson G, Hotchkiss E, Alexander C, May S, Gilray J, Connelly L, Hadfield SJ.</emphasis> 2017. Suitability of loci for multiple-locus variable-number of tandem-repeats analysis of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> for inter-laboratory surveillance and outbreak investigations. <citetitle><emphasis>Parasitology</emphasis></citetitle> <emphasis role="strong">144:</emphasis>37–47.</para>
          </listitem>
          <listitem id="ch0169s000000li0199" role="bibliographyEntry">
            <para>199.<emphasis role="strong">Hadfield SJ, Pachebat JA, Swain MT, Robinson G, Cameron SJ, Alexander J, Hegarty MJ, Elwin K, Chalmers RM.</emphasis> 2015. Generation of whole genome sequences of new <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> and <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> isolates directly from stool samples. <citetitle><emphasis>BMC Genomics</emphasis></citetitle> <emphasis role="strong">16:</emphasis>650.</para>
          </listitem>
          <listitem id="ch0169s000000li0200" role="bibliographyEntry">
            <para>200.<emphasis role="strong">Guo Y, Li N, Lysén C, Frace M, Tang K, Sammons S, Roellig DM, Feng Y, Xiao L.</emphasis> 2015. Isolation and enrichment of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> DNA and verification of DNA purity for whole-genome sequencing. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>641–647.</para>
          </listitem>
          <listitem id="ch0169s000000li0201" role="bibliographyEntry">
            <para>201.<emphasis role="strong">Andersson S, Sikora P, Karlberg ML, Winiecka-Krusnell J, Alm E, Beser J, Arrighi RB.</emphasis> 2015. It’s a dirty job—a robust method for the purification and de novo genome assembly of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> from clinical material. <citetitle><emphasis>J Microbiol Methods</emphasis></citetitle> <emphasis role="strong">113:</emphasis>10–12.</para>
          </listitem>
          <listitem id="ch0169s000000li0202" role="bibliographyEntry">
            <para>202.<emphasis role="strong">Troell K, Hallström B, Divne AM, Alsmark C, Arrighi R, Huss M, Beser J, Bertilsson S.</emphasis> 2016. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> as a testbed for single cell genome characterization of unicellular eukaryotes. <citetitle><emphasis>BMC Genomics</emphasis></citetitle> <emphasis role="strong">17:</emphasis>471.</para>
          </listitem>
          <listitem id="ch0169s000000li0203" role="bibliographyEntry">
            <para>203.<emphasis role="strong">Fan Y, Feng Y, Xiao L.</emphasis> 2019. Comparative genomics: how has it advanced our knowledge of cryptosporidiosis epidemiology? <citetitle><emphasis>Parasitol Res</emphasis></citetitle> <emphasis role="strong">118:</emphasis>3195–3204.</para>
          </listitem>
          <listitem id="ch0169s000000li0204" role="bibliographyEntry">
            <para>204.<emphasis role="strong">Morris A, Robinson G, Swain MT, Chalmers RM.</emphasis> 2019. Direct sequencing of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> in stool samples for public health. <citetitle><emphasis>Front Public Health</emphasis></citetitle> <emphasis role="strong">7:</emphasis>360.</para>
          </listitem>
          <listitem id="ch0169s000000li0205" role="bibliographyEntry">
            <para>205.<emphasis role="strong">Cabarcas F, Galvan-Diaz AL, Arias-Agudelo LM, García-Montoya GM, Daza JM, Alzate JF.</emphasis> 2021. <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> phylogenomic analysis reveals separate lineages with continental segregation. <citetitle><emphasis>Front Genet</emphasis></citetitle> <emphasis role="strong">12:</emphasis>740940.</para>
          </listitem>
          <listitem id="ch0169s000000li0206" role="bibliographyEntry">
            <para>206.<emphasis role="strong">Arias-Agudelo LM, Garcia-Montoya G, Cabarcas F, Galvan-Diaz AL, Alzate JF.</emphasis> 2020. Comparative genomic analysis of the principal <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species that infect humans. <citetitle><emphasis>PeerJ</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e10478.</para>
          </listitem>
          <listitem id="ch0169s000000li0207" role="bibliographyEntry">
            <para>207.<emphasis role="strong">Sikora P, Andersson S, Winiecka-Krusnell J, Hallström B, Alsmark C, Troell K, Beser J, Arrighi RB.</emphasis> 2017. Genomic variation in IbA10G2 and other patient-derived <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> subtypes. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>844–858.</para>
          </listitem>
          <listitem id="ch0169s000000li0208" role="bibliographyEntry">
            <para>208.<emphasis role="strong">Nader JL, Mathers TC, Ward BJ, Pachebat JA, Swain MT, Robinson G, Chalmers RM, Hunter PR, van Oosterhout C, Tyler KM.</emphasis> 2019. Evolutionary genomics of anthroponosis in <citetitle><emphasis>Cryptosporidium. Nat Microbiol</emphasis></citetitle> <emphasis role="strong">4:</emphasis>826–836.</para>
          </listitem>
          <listitem id="ch0169s000000li0209" role="bibliographyEntry">
            <para>209.<emphasis role="strong">Feng Y, Torres E, Li N, Wang L, Bowman D, Xiao L.</emphasis> 2013. Population genetic characterisation of dominant <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> subtype IIaA15G2R1. <citetitle><emphasis>Int J Parasitol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>1141–1147.</para>
          </listitem>
          <listitem id="ch0169s000000li0210" role="bibliographyEntry">
            <para>210.<emphasis role="strong">Guo Y, Tang K, Rowe LA, Li N, Roellig DM, Knipe K, Frace M, Yang C, Feng Y, Xiao L.</emphasis> 2015. Comparative genomic analysis reveals occurrence of genetic recombination in virulent <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> subtypes and telomeric gene duplications in <citetitle><emphasis>Cryptosporidium parvum. BMC Genomics</emphasis></citetitle> <emphasis role="strong">16:</emphasis>320.</para>
          </listitem>
          <listitem id="ch0169s000000li0211" role="bibliographyEntry">
            <para>211.<emphasis role="strong">Cardenas D, Bhalchandra S, Lamisere H, Chen Y, Zeng XL, Ramani S, Karandikar UC, Kaplan DL, Estes MK, Ward HD.</emphasis> 2020. Two- and three-dimensional bioengineered human intestinal tissue models for <citetitle><emphasis>Cryptosporidium. Methods Mol Biol</emphasis></citetitle> <emphasis role="strong">2052:</emphasis>373–402.</para>
          </listitem>
          <listitem id="ch0169s000000li0212" role="bibliographyEntry">
            <para>212.<emphasis role="strong">Yang B, Wang D, Liu M, Wu X, Yin J, Zhu G.</emphasis> 2021. Host cells with transient overexpression of MDR1 as a novel in vitro model for evaluating on-target effect for activity against the epicellular <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> parasite. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">77:</emphasis>124–134.</para>
          </listitem>
          <listitem id="ch0169s000000li0213" role="bibliographyEntry">
            <para>213.<emphasis role="strong">Vélez J, Velasquez Z, Silva LMR, Gärtner U, Failing K, Daugschies A, Mazurek S, Hermosilla C, Taubert A.</emphasis> 2021. Metabolic signatures of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle>-infected HCT-8 cells and impact of selected metabolic inhibitors on <citetitle><emphasis>C. parvum</emphasis></citetitle> infection under physioxia and hyperoxia. <citetitle><emphasis>Biology (Basel)</emphasis></citetitle> 10:60.</para>
          </listitem>
          <listitem id="ch0169s000000li0214" role="bibliographyEntry">
            <para>214.<emphasis role="strong">Li T, Liu H, Jiang N, Wang Y, Wang Y, Zhang J, Shen Y, Cao J.</emphasis> 2021. Comparative proteomics reveals <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> manipulation of the host cell molecular expression and immune response. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>e0009949.</para>
          </listitem>
          <listitem id="ch0169s000000li0215" role="bibliographyEntry">
            <para>215.<emphasis role="strong">Diawara EH, François A, Stachulski AV, Razakandrainibe R, Costa D, Favennec L, Rossignol JF, Gargala G.</emphasis> 2021. Systemic efficacy on <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> infection of aminoxanide (RM-5061), a new amino-acid ester thiazolide prodrug of tizoxanide. <citetitle><emphasis>Parasitology</emphasis></citetitle> <emphasis role="strong">148:</emphasis>975–984.</para>
          </listitem>
          <listitem id="ch0169s000000li0216" role="bibliographyEntry">
            <para>216.<emphasis role="strong">Love MS, McNamara CW.</emphasis> 2020. High-content screening for <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> drug discovery. <citetitle><emphasis>Methods Mol Biol</emphasis></citetitle> <emphasis role="strong">2052:</emphasis>303–317.</para>
          </listitem>
          <listitem id="ch0169s000000li0217" role="bibliographyEntry">
            <anchor id="ch0169s000000a0082"/>
            <para>217.<emphasis role="strong">Jaskiewicz JJ, Sevenler D, Swei AA, Widmer G, Toner M, Tzipori S, Sandlin RD.</emphasis> 2020. Cryopreservation of infectious <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> oocysts achieved through vitrification using high aspect ratio specimen containers. <citetitle><emphasis>Sci Rep</emphasis></citetitle> <emphasis role="strong">10:</emphasis>11711.</para>
          </listitem>
          <listitem id="ch0169s000000li0218" role="bibliographyEntry">
            <para>218.<emphasis role="strong">Paziewska-Harris A, Schoone G, Schallig HDFH.</emphasis> 2018. Long-term storage of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> for in vitro culture. <citetitle><emphasis>J Parasitol</emphasis></citetitle> <emphasis role="strong">104:</emphasis>96–100.</para>
          </listitem>
          <listitem id="ch0169s000000li0219" role="bibliographyEntry">
            <para>219.<emphasis role="strong">Jaskiewicz JJ, Sandlin RD, Swei AA, Widmer G, Toner M, Tzipori S.</emphasis> 2018. Cryopreservation of infectious <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> oocysts. <citetitle><emphasis>Nat Commun</emphasis></citetitle> <emphasis role="strong">9:</emphasis>2883.</para>
          </listitem>
          <listitem id="ch0169s000000li0220" role="bibliographyEntry">
            <para>220.<emphasis role="strong">Bhalchandra S, Lamisere H, Ward H.</emphasis> 2020. Intestinal organoid/enteroid-based models for <citetitle><emphasis>Cryptosporidium. Curr Opin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>124–129.</para>
          </listitem>
          <listitem id="ch0169s000000li0221" role="bibliographyEntry">
            <para>221.<emphasis role="strong">Wilke G, Funkhouser-Jones LJ, Wang Y, Ravindran S, Wang Q, Beatty WL, Baldridge MT, VanDussen KL, Shen B, Kuhlenschmidt MS, Kuhlenschmidt TB, Witola WH, Stappenbeck TS, Sibley LD.</emphasis> 2019. A stem-cell-derived platform enables complete <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> development in vitro and genetic tractability. <citetitle><emphasis>Cell Host Microbe</emphasis></citetitle> <emphasis role="strong">26:</emphasis>123–134.e8.</para>
          </listitem>
          <listitem id="ch0169s000000li0222" role="bibliographyEntry">
            <para>222.<emphasis role="strong">Schneider A, Wendt S, Lübbert C, Trawinski H.</emphasis> 2021. Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art. <citetitle><emphasis>Expert Opin Pharmacother</emphasis></citetitle> <emphasis role="strong">22:</emphasis>2337–2342.</para>
          </listitem>
          <listitem id="ch0169s000000li0223" role="bibliographyEntry">
            <para>223.<emphasis role="strong">Love MS, Choy RKM.</emphasis> 2021. Emerging treatment options for cryptosporidiosis. <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">34:</emphasis>455–462.</para>
          </listitem>
          <listitem id="ch0169s000000li0224" role="bibliographyEntry">
            <para>224.<emphasis role="strong">Diptyanusa A, Sari IP.</emphasis> 2021. Treatment of human intestinal cryptosporidiosis: a review of published clinical trials. <citetitle><emphasis>Int J Parasitol Drugs Drug Resist</emphasis></citetitle> <emphasis role="strong">17:</emphasis>128–138.</para>
          </listitem>
          <listitem id="ch0169s000000li0225" role="bibliographyEntry">
            <para>225.<emphasis role="strong">McLeod C, Morris PS, Snelling TL, Carapetis JR, Bowen AC.</emphasis> 2014. Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007–2012. <citetitle><emphasis>Rural Remote Health</emphasis></citetitle> <emphasis role="strong">14:</emphasis>2759.</para>
          </listitem>
          <listitem id="ch0169s000000li0226" role="bibliographyEntry">
            <para>226.<emphasis role="strong">Ali S, Mumar S, Kalam K, Raja K, Baqi S.</emphasis> 2014. Prevalence, clinical presentation and treatment outcome of cryptosporidiosis in immunocompetent adult patients presenting with acute diarrhoea. <citetitle><emphasis>J Pak Med Assoc</emphasis></citetitle> <emphasis role="strong">64:</emphasis>613–618.</para>
          </listitem>
          <listitem id="ch0169s000000li0227" role="bibliographyEntry">
            <para>227.<emphasis role="strong">Chavez MA, White AC Jr.</emphasis> 2018. Novel treatment strategies and drugs in development for cryptosporidiosis. <citetitle><emphasis>Expert Rev Anti Infect Ther</emphasis></citetitle> <emphasis role="strong">16:</emphasis>655–661.</para>
          </listitem>
          <listitem id="ch0169s000000li0228" role="bibliographyEntry">
            <para>228.<emphasis role="strong">Iroh Tam PY, Arnold SLM, Barrett LK, Chen CR, Conrad TM, Douglas E, Gordon MA, Hebert D, Henrion M, Hermann D, Hollingsworth B, Houpt E, Jere KC, Lindblad R, Love MS, Makhaza L, McNamara CW, Nedi W, Nyirenda J, Operario DJ, Phulusa J, Quinnan GV, Sawyer LA, Thole H, Toto N, Winter A, Van Voorhis WC.</emphasis> 2020. Clofazimine for treatment of cryptosporidiosis in HIV-infected adults: an experimental medicine, randomized, double-blind, placebo-controlled phase 2a trial. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>183–191.</para>
          </listitem>
          <listitem id="ch0169s000000li0229" role="bibliographyEntry">
            <para>229.<emphasis role="strong">Mengist HM, Taye B, Tsegaye A.</emphasis> 2015. Intestinal parasitosis in relation to CD4+T cells levels and anemia among HAART initiated and HAART naive pediatric HIV patients in a model ART center in Addis Ababa, <citetitle><emphasis>Ethiopia. PLoS One</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e0117715.</para>
          </listitem>
          <listitem id="ch0169s000000li0230" role="bibliographyEntry">
            <para>230.<emphasis role="strong">Kaniyarakkal V, Mundangalam N, Moorkoth AP, Mathew S.</emphasis> 2016. Intestinal parasite profile in the stool of HIV positive patients in relation to immune status and comparison of various diagnostic techniques with special reference to <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> at a tertiary care hospital in South India. <citetitle><emphasis>Adv Med</emphasis></citetitle> <emphasis role="strong">2016:</emphasis>3564359.</para>
          </listitem>
          <listitem id="ch0169s000000li0231" role="bibliographyEntry">
            <para>231.<emphasis role="strong">Ndao M, Nath-Chowdhury M, Sajid M, Marcus V, Mashiyama ST, Sakanari J, Chow E, Mackey Z, Land KM, Jacobson MP, Kalyanaraman C, McKerrow JH, Arrowood MJ, Caffrey CR.</emphasis> 2013. A cysteine protease inhibitor rescues mice from a lethal <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> infection. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>6063–6073.</para>
          </listitem>
          <listitem id="ch0169s000000li0232" role="bibliographyEntry">
            <para>232.<emphasis role="strong">Akinbo FO, Okaka CE, Omoregie R, Adamu H, Xiao L.</emphasis> 2013. Unusual <citetitle><emphasis>Enterocytozoon bieneusi</emphasis></citetitle> genotypes and <citetitle><emphasis>Cryptosporidium hominis</emphasis></citetitle> subtypes in HIV-infected patients on highly active antiretroviral therapy. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">89:</emphasis>157–161.</para>
          </listitem>
          <listitem id="ch0169s000000li0233" role="bibliographyEntry">
            <para>233.<emphasis role="strong">Ukwah BN, Ezeonu IM, Ezeonu CT, Roellig D, Xiao L.</emphasis> 2017. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> species and subtypes in diarrheal children and HIV-infected persons in Ebonyi and Nsukka, Nigeria. <citetitle><emphasis>J Infect Dev Ctries</emphasis></citetitle> <emphasis role="strong">11:</emphasis>173–179.</para>
          </listitem>
          <listitem id="ch0169s000000li0234" role="bibliographyEntry">
            <para>234.<emphasis role="strong">Utami WS, Murhandarwati EH, Artama WT, Kusnanto H.</emphasis> 2020. <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection increases the risk for chronic diarrhea among people living with HIV in Southeast Asia: a systematic review and meta-analysis. <citetitle><emphasis>Asia Pac J Public Health</emphasis></citetitle> <emphasis role="strong">32:</emphasis>8–18.</para>
          </listitem>
          <listitem id="ch0169s000000li0235" role="bibliographyEntry">
            <para>235.<emphasis role="strong">Chellan P, Sadler PJ, Land KM.</emphasis> 2017. Recent developments in drug discovery against the protozoal parasites <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> and <citetitle><emphasis>Toxoplasma. Bioorg Med Chem Lett</emphasis></citetitle> <emphasis role="strong">27:</emphasis>1491–1501.</para>
          </listitem>
          <listitem id="ch0169s000000li0236" role="bibliographyEntry">
            <para>236.<emphasis role="strong">Shoultz DA, de Hostos EL, Choy RK.</emphasis> 2016. Addressing <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection among young children in low-income settings: the crucial role of new and existing drugs for reducing morbidity and mortality. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e0004242.</para>
          </listitem>
          <listitem id="ch0169s000000li0237" role="bibliographyEntry">
            <para>237.<emphasis role="strong">Debnath A, McKerrow JH.</emphasis> 2017. Editorial: drug development for parasite-induced diarrheal diseases. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>577.</para>
          </listitem>
          <listitem id="ch0169s000000li0238" role="bibliographyEntry">
            <para>238.<emphasis role="strong">Wang B, Castellanos-Gonzalez A, White AC Jr.</emphasis> 2020. Novel drug targets for treatment of cryptosporidiosis. <citetitle><emphasis>Expert Opin Ther Targets</emphasis></citetitle> <emphasis role="strong">24:</emphasis>915–922.</para>
          </listitem>
          <listitem id="ch0169s000000li0239" role="bibliographyEntry">
            <para>239.<emphasis role="strong">Jumani RS, Hasan MM, Stebbins EE, Donnelly L, Miller P, Klopfer C, Bessoff K, Teixeira JE, Love MS, McNamara CW, Huston CD.</emphasis> 2019. A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> growth inhibitors. <citetitle><emphasis>Nat Commun</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1862.</para>
          </listitem>
          <listitem id="ch0169s000000li0240" role="bibliographyEntry">
            <para>240.<emphasis role="strong">Ward HD.</emphasis> 2017. New tools for <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> lead to new hope for cryptosporidiosis. <citetitle><emphasis>Trends Parasitol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>662–664.</para>
          </listitem>
          <listitem id="ch0169s000000li0241" role="bibliographyEntry">
            <para>241.<emphasis role="strong">Sateriale A, Pawlowic M, Vinayak S, Brooks C, Striepen B.</emphasis> 2020. Genetic manipulation of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> with CRISPR/Cas9. <citetitle><emphasis>Methods Mol Biol</emphasis></citetitle> <emphasis role="strong">2052:</emphasis>219–228.</para>
          </listitem>
          <listitem id="ch0169s000000li0242" role="bibliographyEntry">
            <para>242.<emphasis role="strong">Van Voorhis WC, Hulverson MA, Choi R, Huang W, Arnold SLM, Schaefer DA, Betzer DP, Vidadala RSR, Lee S, Whitman GR, Barrett LK, Maly DJ, Riggs MW, Fan E, Kennedy TJ, Tzipori S, Doggett JS, Winzer P, Anghel N, Imhof D, Müller J, Hemphill A, Ferre I, Sanchez-Sanchez R, Ortega-Mora LM, Ojo KK.</emphasis> 2021. One Health therapeutics: target-based drug development for cryptosporidiosis and other apicomplexa diseases. <citetitle><emphasis>Vet Parasitol</emphasis></citetitle> <emphasis role="strong">289:</emphasis>109336.</para>
          </listitem>
          <listitem id="ch0169s000000li0243" role="bibliographyEntry">
            <para>243.<emphasis role="strong">Manjunatha UH, Vinayak S, Zambriski JA, Chao AT, Sy T, Noble CG, Bonamy GMC, Kondreddi RR, Zou B, Gedeck P, Brooks CF, Herbert GT, Sateriale A, Tandel J, Noh S, Lakshminarayana SB, Lim SH, Goodman LB, Bodenreider C, Feng G, Zhang L, Blasco F, Wagner J, Leong FJ, Striepen B, Diagana TT.</emphasis> 2017. A <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> PI(<link linkend="ch0169s000000li0004">4</link>)K inhibitor is a drug candidate for cryptosporidiosis. <citetitle><emphasis>Nature</emphasis></citetitle> <emphasis role="strong">546:</emphasis>376–380.</para>
          </listitem>
          <listitem id="ch0169s000000li0244" role="bibliographyEntry">
            <para>244.<emphasis role="strong">Castellanos-Gonzalez A, Sparks H, Nava S, Huang W, Zhang Z, Rivas K, Hulverson MA, Barrett LK, Ojo KK, Fan E, Van Voorhis WC, White AC Jr.</emphasis> 2016. A novel calcium-dependent kinase inhibitor, bumped kinase inhibitor 1517, cures cryptosporidiosis in immunosuppressed mice. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">214:</emphasis>1850–1855.</para>
          </listitem>
          <listitem id="ch0169s000000li0245" role="bibliographyEntry">
            <para>245.<emphasis role="strong">Hulverson MA, Vinayak S, Choi R, Schaefer DA, Castellanos-Gonzalez A, Vidadala RSR, Brooks CF, Herbert GT, Betzer DP, Whitman GR, Sparks HN, Arnold SLM, Rivas KL, Barrett LK, White AC Jr, Maly DJ, Riggs MW, Striepen B, Van Voorhis WC, Ojo KK.</emphasis> 2017. Bumped-kinase inhibitors for cryptosporidiosis therapy. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">215:</emphasis>1275–1284.</para>
          </listitem>
          <listitem id="ch0169s000000li0246" role="bibliographyEntry">
            <para>246.<emphasis role="strong">Arnold SLM, Choi R, Hulverson MA, Schaefer DA, Vinayak S, Vidadala RSR, McCloskey MC, Whitman GR, Huang W, Barrett LK, Ojo KK, Fan E, Maly DJ, Riggs MW, Striepen B, Van Voorhis WC.</emphasis> 2017. Necessity of bumped kinase inhibitor gastrointestinal exposure in treating <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infection. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">216:</emphasis>55–63.</para>
          </listitem>
          <listitem id="ch0169s000000li0247" role="bibliographyEntry">
            <para>247.<emphasis role="strong">Huang W, Choi R, Hulverson MA, Zhang Z, McCloskey MC, Schaefer DA, Whitman GR, Barrett LK, Vidadala RSR, Riggs MW, Maly DJ, Van Voorhis WC, Ojo KK, Fan E.</emphasis> 2017. 5-Aminopyrazole-4-carboxamide-based compounds prevent the growth of <citetitle><emphasis>Cryptosporidium parvum. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e00020–17.</para>
          </listitem>
          <listitem id="ch0169s000000li0248" role="bibliographyEntry">
            <para>248.<emphasis role="strong">Osman KT, Ye J, Shi Z, Toker C, Lovato D, Jumani RS, Zuercher W, Huston CD, Edwards AM, Lautens M, Santhakumar V, Hui R.</emphasis> 2017. Discovery and structure activity relationship of the first potent <citetitle><emphasis>cryptosporidium</emphasis></citetitle> FIKK kinase inhibitor. <citetitle><emphasis>Bioorg Med Chem</emphasis></citetitle> <emphasis role="strong">25:</emphasis>1672–1680.</para>
          </listitem>
          <listitem id="ch0169s000000li0249" role="bibliographyEntry">
            <para>249.<emphasis role="strong">Funkhouser-Jones LJ, Ravindran S, Sibley LD.</emphasis> 2020. Defining stage-specific activity of potent new inhibitors of <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> growth in vitro. <citetitle><emphasis>MBio</emphasis></citetitle> <emphasis role="strong">11:</emphasis>e00052–20.</para>
          </listitem>
          <listitem id="ch0169s000000li0250" role="bibliographyEntry">
            <anchor id="ch0169s000000a0083"/>
            <para>250.<emphasis role="strong">Jumani RS, Bessoff K, Love MS, Miller P, Stebbins EE, Teixeira JE, Campbell MA, Meyers MJ, Zambriski JA, Nunez V, Woods AK, McNamara CW, Huston CD.</emphasis> 2018. A novel piperazine-based drug lead for cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">62:</emphasis>e01505–17.</para>
          </listitem>
          <listitem id="ch0169s000000li0251" role="bibliographyEntry">
            <para>251.<emphasis role="strong">Lee S, Ginese M, Girouard D, Beamer G, Huston CD, Osbourn D, Griggs DW, Tzipori S.</emphasis> 2019. Piperazine-derivative MMV665917: an effective drug in the diarrheic piglet model of <citetitle><emphasis>Cryptosporidium hominis. J Infect Dis</emphasis></citetitle> <emphasis role="strong">220:</emphasis>285–293.</para>
          </listitem>
          <listitem id="ch0169s000000li0252" role="bibliographyEntry">
            <para>252.<emphasis role="strong">Stebbins E, Jumani RS, Klopfer C, Barlow J, Miller P, Campbell MA, Meyers MJ, Griggs DW, Huston CD.</emphasis> 2018. Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0006183.</para>
          </listitem>
          <listitem id="ch0169s000000li0253" role="bibliographyEntry">
            <para>253.<emphasis role="strong">Lunde CS, Stebbins EE, Jumani RS, Hasan MM, Miller P, Barlow J, Freund YR, Berry P, Stefanakis R, Gut J, Rosenthal PJ, Love MS, McNamara CW, Easom E, Plattner JJ, Jacobs RT, Huston CD.</emphasis> 2019. Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. <citetitle><emphasis>Nat Commun</emphasis></citetitle> <emphasis role="strong">10:</emphasis>2816.</para>
          </listitem>
          <listitem id="ch0169s000000li0254" role="bibliographyEntry">
            <para>254.<emphasis role="strong">Hulverson MA, Choi R, Vidadala RSR, Whitman GR, Vidadala VN, Ojo KK, Barrett LK, Lynch JJ, Marsh K, Kempf DJ, Maly DJ, Van Voorhis WC.</emphasis> 2021. Pyrrolopyrimidine bumped kinase inhibitors for the treatment of cryptosporidiosis. <citetitle><emphasis>ACS Infect Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>1200–1207.</para>
          </listitem>
          <listitem id="ch0169s000000li0255" role="bibliographyEntry">
            <para>255.<emphasis role="strong">Hulverson MA, Choi R, McCloskey MC, Whitman GR, Ojo KK, Michaels SA, Somepalli M, Love MS, McNamara CW, Rabago LM, Barrett LK, Verlinde CLMJ, Arnold SLM, Striepen B, Jimenez-Alfaro D, Ballell L, Fernández E, Greenwood MN, Las Heras L, Calderón F, Van Voorhis WC.</emphasis> 2021. Repurposing infectious disease hits as anti-<citetitle><emphasis>Cryptosporidium</emphasis></citetitle> leads. <citetitle><emphasis>ACS Infect Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>1275–1282.</para>
          </listitem>
          <listitem id="ch0169s000000li0256" role="bibliographyEntry">
            <para>256.<emphasis role="strong">Julian TR.</emphasis> 2016. Environmental transmission of diarrheal pathogens in low and middle income countries. <citetitle><emphasis>Environ Sci Process Impacts</emphasis></citetitle> <emphasis role="strong">18:</emphasis>944–955.</para>
          </listitem>
          <listitem id="ch0169s000000li0257" role="bibliographyEntry">
            <para>257.<emphasis role="strong">Shrivastava AK, Kumar S, Smith WA, Sahu PS.</emphasis> 2017. Revisiting the global problem of cryptosporidiosis and recommendations. <citetitle><emphasis>Trop Parasitol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>8–17.</para>
          </listitem>
          <listitem id="ch0169s000000li0258" role="bibliographyEntry">
            <para>258.<emphasis role="strong">Omarova A, Tussupova K, Berndtsson R, Kalishev M, Sharapatova K.</emphasis> 2018. Protozoan parasites in drinking water: a system approach for improved water, sanitation and hygiene in developing countries. <citetitle><emphasis>Int J Environ Res Public Health</emphasis></citetitle> <emphasis role="strong">15:</emphasis>495.</para>
          </listitem>
          <listitem id="ch0169s000000li0259" role="bibliographyEntry">
            <para>259.<emphasis role="strong">Ross AG, Rahman M, Alam M, Zaman K, Qadri F.</emphasis> 2020. Can we ‘WaSH’ infectious diseases out of slums? <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">92:</emphasis>130–132.</para>
          </listitem>
          <listitem id="ch0169s000000li0260" role="bibliographyEntry">
            <para>260.<emphasis role="strong">Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America.</emphasis> 2009. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">58</emphasis>(RR-4)<emphasis role="strong">:</emphasis>1–207, quiz CE1–CE4.</para>
          </listitem>
          <listitem id="ch0169s000000li0261" role="bibliographyEntry">
            <para>261.<emphasis role="strong">Innes EA, Chalmers RM, Wells B, Pawlowic MC.</emphasis> 2020. A one health approach to tackle cryptosporidiosis. <citetitle><emphasis>Trends Parasitol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>290–303.</para>
          </listitem>
          <listitem id="ch0169s000000li0262" role="bibliographyEntry">
            <para>262.<emphasis role="strong">Elfving K, Andersson M, Msellem MI, Welinder-Olsson C, Petzold M, Björkman A, Trollfors B, Mårtensson A, Lindh M.</emphasis> 2014. Real-time PCR threshold cycle cutoffs help to identify agents causing acute childhood diarrhea in Zanzibar. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>916–923.</para>
          </listitem>
          <listitem id="ch0169s000000li0263" role="bibliographyEntry">
            <para>263.<emphasis role="strong">Centers for Disease Control and Prevention (CDC).</emphasis> 2004. Manufacturer’s recall of rapid cartridge assay kits on the basis of false-positive <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> antigen tests—Colorado, 2004. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">53:</emphasis>198.</para>
          </listitem>
          <listitem id="ch0169s000000li0264" role="bibliographyEntry">
            <para>264.<emphasis role="strong">Fournet N, Deege MP, Urbanus AT, Nichols G, Rosner BM, Chalmers RM, Gorton R, Pollock KG, van der Giessen JW, Wever PC, Dorigo-Zetsma JW, Mulder B, Mank TG, Overdevest I, Kusters JG, van Pelt W, Kortbeek LM.</emphasis> 2013. Simultaneous increase of <citetitle><emphasis>Cryptosporidium</emphasis></citetitle> infections in the Netherlands, the United Kingdom and Germany in late summer season, 2012. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">18:</emphasis>20348.</para>
          </listitem>
          <listitem id="ch0169s000000li0265" role="bibliographyEntry">
            <para>265.<emphasis role="strong">Ježková J, Limpouchová Z, Prediger J, Holubová N, Sak B, Konečný R, Květoňová D, Hlásková L, Rost M, McEvoy J, Rajský D, Feng Y, Kvá</emphasis>č <emphasis role="strong">M.</emphasis> 2021. <citetitle><emphasis>Cryptosporidium myocastoris</emphasis></citetitle> n. sp. (Apicomplexa: Cryptosporidiidae), the species adapted to the nutria (<citetitle><emphasis>Myocastor coypus</emphasis></citetitle>). <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">9:</emphasis>813.</para>
          </listitem>
          <listitem id="ch0169s000000li0266" role="bibliographyEntry">
            <para>266.<emphasis role="strong">English ED, Guerin A, Tandel J, Striepen B.</emphasis> 2022. Live imaging of the <citetitle><emphasis>Cryptosporidium parvum</emphasis></citetitle> life cycle reveals direct development of male and female gametes from type I meronts. <citetitle><emphasis>PLoS Biol</emphasis></citetitle> <emphasis role="strong">20:</emphasis>e3001604.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0169s000000a0076"/>
        <beginpage pagenum="2887"/>
      </sect2>
    </sect1>
  </chapter>
